case_id,mode,case_type,iteration,Q0_answer,Q0_reasoning,Q1_answer,Q1_reasoning,Q2_answer,Q2_reasoning,Q3_answer,Q3_reasoning,Q4_answer,Q4_reasoning,Q5_answer,Q5_reasoning,Q6_answer,Q6_reasoning,Q7_answer,Q7_reasoning,Q8_answer,Q8_reasoning,input_tokens,output_tokens,total_tokens
Case3223,baseline,without_policy,iter2,BRCA1/2,Request was specifically for BRCA1 and BRCA2 testing for hereditary breast/ovarian cancer risk given a sister with epithelial ovarian cancer.,Not Specified,BCBS_FEP BRCA coverage criteria are based on personal/family cancer history rather than strict age limits; no age-based exclusion applies to this request.,Not Specified,BCBS_FEP policies specify requirements around genetic counseling and appropriate documentation rather than a narrow ordering-provider specialty requirement; the patient information does not state any provider-specialty restriction.,Yes,Medical indication met: an unaffected individual with a first-degree relative (sister) diagnosed with epithelial ovarian cancer meets BCBS_FEP clinical criteria for BRCA testing.,Not Specified,BCBS_FEP BRCA coverage does not require completion of prior diagnostic genetic tests (the prior nondiagnostic CMA is unrelated); no specific prior-test prerequisite is documented for BRCA testing.,Yes,"Family-history criterion met: patient has a first-degree relative with ovarian cancer, which is a specified qualifying family history for BRCA testing under the payer policy.",No,BCBS_FEP requires documentation of pre-test genetic counseling/informed consent for hereditary cancer testing; the record states no documentation of pre-test genetic counseling.,Not Specified,"Standard CPT codes for BRCA1/BRCA2 (e.g., 81211, 81213) are not among the provided options, so none of the listed codes clearly correspond to BRCA1/2 full testing.",No,"Although the patient meets clinical/family-history indications for BRCA testing under BCBS_FEP, coverage requires documented pre-test genetic counseling; absence of that documentation means the request does not meet all payer coverage/counseling requirements.",1963,2382,4345
Case14226,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states germline BRCA1 and BRCA2 (BRCA1/2) testing is being pursued.,Not Specified,Cigna BRCA testing policy does not impose a specific age cutoff for adult BRCA1/2 germline testing; the patient is an adult (55) and no age exclusion is cited in policy.,Not Specified,Cigna typically requires an appropriate ordering clinician but does not restrict testing to a narrow specialty in its BRCA policy; the information states oncology is ordering the test but the policy does not specify a single required provider type.,No,"Cigna coverage for BRCA1/2 requires specific clinical indications (personal history of qualifying cancers or family history/validated risk-model threshold per policy/NCCN). The patient has a non-breast/ovarian qualifying solid tumor and a calculated BRCA risk of 2.5%, which is below typical Cigna-required thresholds and does not meet listed medical indications.",Not Specified,"Cigna BRCA criteria do not mandate completion of prior diagnostic genetic tests before ordering germline BRCA testing; the patient has no prior germline testing, which is acceptable but no specific prior-test requirement is specified.",No,"Cigna specifies family history of breast, ovarian, pancreatic, or related cancers as relevant for BRCA eligibility; the documented family history (mother with a hematologic/immunologic disorder) is not one of the specified BRCA-relevant conditions.",No,"Cigna policy expects documentation of pre-test genetic counseling for germline BRCA testing. The record states no pre-test counseling was completed, so counseling requirements are not met.",81277,"Of the provided CPT options, 81277 most closely corresponds to BRCA1/BRCA2 gene testing among the choices (single-gene/two-gene hereditary cancer testing) and is the best match for a BRCA1/2 germline assay.",No,Under Cigna BRCA coverage criteria the patient does not meet medical indication thresholds (calculated risk too low and personal/family history not qualifying) and pre-test genetic counseling is not documented; therefore the requested BRCA1/2 test is not covered.,2026,2095,4121
Case10451,baseline,without_policy,iter2,WES,The clinical note explicitly states the neurologist referred the patient for whole exome sequencing (WES) to evaluate an unexplained neurodevelopmental disorder.,Yes,UHC coverage for WES includes pediatric patients with unexplained moderate-to-severe intellectual disability diagnosed in childhood; the patient is 10 years old and therefore meets age‑based pediatric criteria.,Not Specified,"UHC policies generally require an appropriately qualified ordering clinician but do not strictly limit orders to a specific specialty in all cases; the neurologist placed the order, which is typically acceptable, and no explicit payer-only-specialty restriction is documented in the provided information.",Yes,"UHC medical necessity criteria for WES include unexplained moderate-to-severe intellectual disability / neurodevelopmental disorder; the patient has moderate-to-severe intellectual disability of childhood onset and an unexplained neurodevelopmental disorder, meeting the indication.",Not Answerable,"The record documents prior CMA testing was nondiagnostic (which satisfies one common prerequisite), but UHC often also requires Fragile X testing in males prior to WES. Patient sex is not provided, so it cannot be determined whether all required prior tests were completed.",Not Specified,"UHC WES coverage is based primarily on the proband's clinical features and prior testing; while a sibling had a brief resolved unexplained event, family history/consanguinity criteria relevant to WES eligibility are not specified in the provided policy context.",No,"UHC policies for WES typically require documentation of pre-test genetic counseling/informed consent by a qualified provider. The record states there is no documentation of prior genetic counseling, so the counseling requirement is not met.",81415,CPT code 81415 corresponds to clinical exome sequencing (WES) and is the appropriate billing code among the listed options for the requested test.,No,"Although the patient meets age and clinical indication and has a nondiagnostic CMA, UHC coverage requires completion/documentation of all prerequisite testing (e.g., Fragile X when applicable) and documented pre-test genetic counseling. Because counseling is not documented and prior-test completeness cannot be confirmed (sex not provided for Fragile X requirement), coverage criteria are not fully met and the test would be denied pending completion/documentation of those requirements.",1999,2041,4040
Case4196,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested as the next diagnostic step.,Not Specified,"BCBS FEP WES coverage criteria do not impose a strict single age cutoff; WES indications are clinical (developmental delay/ID) rather than limited to a specific numeric age, so no specific age-based exclusion applies to this 10-year-old.",Not Specified,"BCBS FEP criteria typically require appropriate clinical documentation and genetic counseling but do not rigidly limit ordering to a single specialty in the policy text; the record shows a referring cardiologist with completed pre-test counseling, which meets typical provider documentation requirements.",Yes,The patient has unexplained developmental delay and intellectual disability with a similarly affected sibling — this meets BCBS FEP clinical indications for diagnostic WES in individuals with unexplained DD/ID after or in the context of prior appropriate cytogenetic testing.,No,"BCBS FEP policy generally requires prior chromosomal microarray (CMA) or equivalent cytogenetic testing before WES for unexplained DD/ID; the record notes prior FISH was nondiagnostic but does not document that CMA has been completed, so required prior testing appears incomplete.",Yes,"Family history is relevant per BCBS FEP criteria; the patient has an affected brother with moderate–severe childhood ID, which supports the clinical rationale for WES and meets family history considerations in policy.",Yes,"BCBS FEP requires pre-test genetic counseling for WES; the record documents that pre-test genetic counseling was completed and post-test follow-up is planned, satisfying counseling requirements.",81415,"CPT 81415 corresponds to clinical exome sequencing (WES) for a proband, which best matches the ordered test.",No,"Although the patient meets clinical indications, BCBS FEP policy requires prior CMA (or equivalent) before WES for unexplained DD/ID; because only FISH (nondiagnostic) is documented and CMA is not documented as completed, coverage would not be authorized until the required prior testing is completed.",1997,1492,3489
Case18281,baseline,without_policy,iter2,WGS,The clinical note explicitly states the cardiologist has ordered whole genome sequencing (WGS).,Not Specified,"UHC sequencing policies do not impose a strict age cutoff for WES/WGS; pediatric patients with congenital anomalies are within typical covered populations, and no age-based exclusion is documented in the clinical information.",Not Specified,UHC policies generally require an appropriate ordering clinician but do not universally restrict ordering to a specific specialty in the provided context; the record shows a cardiologist ordered testing but the policy-specified ordering-provider specialty requirement is not documented in the patient information.,Yes,UHC criteria support WES/WGS for patients with multiple congenital anomalies not fitting a well-delineated syndrome; this 6-year-old has multiple congenital anomalies and thus meets the medical indication for diagnostic sequencing.,No,"UHC coverage for diagnostic sequencing typically requires prior first‑tier testing (e.g., chromosomal microarray); Fragile X was done and nondiagnostic, but there is no documentation that chromosomal microarray (CMA) or other required prior tests were completed.",Yes,"The patient has a relevant family history (a sibling with an inborn error of metabolism), which is pertinent to genetic testing eligibility per UHC criteria and can support molecular diagnostic evaluation.",No,"UHC policies for comprehensive genomic testing typically require pre-test genetic counseling; the record states no genetic counseling was conducted prior to testing, so counseling requirements are unmet.",81425,"CPT 81425 corresponds to whole genome sequencing (WGS) with comprehensive analysis, which maps to the requested WGS.",No,"Although the patient meets the clinical indication (multiple congenital anomalies) and has supportive family history, UHC coverage requires prior first‑tier testing (e.g., CMA) and pre‑test genetic counseling; those prerequisites are not documented (CMA not documented, counseling not performed), so coverage would not be approved at this time.",1982,1652,3634
Case17196,baseline,without_policy,iter2,CMA,The patient is explicitly referred for chromosomal microarray (CMA) testing in the provided clinical information.,Not Specified,"BCBS FEP CMA coverage criteria are indication-based (developmental delay/ID, autism, congenital anomalies) rather than age-limited; no specific age cutoff is specified that would make a 63-year-old ineligible.",Not Specified,BCBS FEP medical policy for CMA focuses on clinical indications; there is no payer-specific ordering-provider specialty requirement documented in the provided facts.,No,"BCBS FEP CMA medical necessity is generally limited to unexplained developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies. The patient has a longstanding psychiatric presentation (bipolar/schizophrenia/OCD features), which does not meet those specified indications.",Not Specified,"BCBS FEP CMA policy does not universally mandate specific prior testing (and CMA is often first-line for developmental delay); while a karyotype was performed and nondiagnostic, the policy does not specify required prior tests in this clinical context.",Not Specified,Family history requirements are not a defined criterion for BCBS FEP CMA coverage in the standard indications; the sibling history of sensory impairment is noted but does not map to a stated family-history-based eligibility rule.,Not Specified,"Pre-test genetic counseling may be best practice, but BCBS FEP CMA coverage criteria focus on clinical indications; a counseling requirement is not specified in the provided payer criteria, and no documented counseling was performed.",81228,"CPT 81228 corresponds to genome-wide chromosomal microarray (constitutional copy number/SNP microarray) testing, which matches the requested CMA.",No,"Applying BCBS FEP coverage criteria: CMA is covered for unexplained developmental delay/intellectual disability, autism, or multiple congenital anomalies. The patient’s indication is a psychiatric/neuropsychiatric presentation (bipolar/schizophrenia/OCD features) in a 63-year-old, which does not meet the payer's specified medical necessity criteria for CMA; prior karyotype was nondiagnostic but does not change the lack of a covered indication.",1992,2019,4011
Case8288,baseline,without_policy,iter2,WES,The case states that whole exome sequencing is being pursued to evaluate an underlying genetic etiology after a nondiagnostic CMA.,Not Specified,"UHC WES coverage criteria do not impose a strict numeric age cutoff; they address clinical scenario (prenatal/major anomaly) rather than a specific patient age, so age-based criteria are not specified.",Not Specified,"UHC coverage policies typically require appropriate clinical ordering but do not mandate a single specific ordering specialty in all cases; the record shows referral by a developmental pediatrician and genetic counseling involvement, but no payer-specific ordering-provider restriction is stated.",Yes,"UHC allows WES for prenatal patients with a major structural fetal anomaly when results could affect perinatal/postnatal management; this fetus has a major cardiac malformation and WES is being requested for management guidance, meeting the clinical indication.",Yes,"UHC generally requires prior chromosomal microarray (and/or karyotype) to be nondiagnostic before WES; the patient had a prior CMA that was nondiagnostic, satisfying prior test requirements.",Yes,"Family history criteria are relevant for coverage and this case reports an older sibling with an inborn error of metabolism, which is pertinent family history supportive of testing.",Yes,"UHC coverage for WES requires genetic counseling/appropriate pre-test counseling; the parents have had multiple sessions with a genetic counselor, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (proband or single exome), which matches the requested WES.",Yes,"Under UHC criteria, prenatal WES is covered for major structural fetal anomalies when prior CMA is nondiagnostic, counseling has occurred, and results may impact management; all these conditions are met in this case.",2018,1364,3382
Case3422,baseline,without_policy,iter2,WES,The clinical note explicitly states consideration of whole-exome sequencing (WES) after a nondiagnostic CMA.,Not Specified,Cigna WES coverage criteria do not impose a strict age cutoff and apply across ages for appropriate indications; no age-based exclusion applies to this 34-year-old.,Not Specified,Cigna's WES policy requires appropriate documentation of clinical indication and informed consent but does not mandate a specific ordering provider specialty in the information provided; the record shows referral by oncology and multiple genetics visits but policy does not specifically require a particular provider type.,No,"Per Cigna WES criteria, WES is generally covered for individuals with unexplained developmental delay/intellectual disability, progressive neurologic disorder, or multiple congenital anomalies or when prior targeted testing strongly suggests broad sequencing. This patient has a single congenital anomaly (choanal atresia) without reported developmental delay or multiple major anomalies, so she does not meet the defined medical indications.",Yes,"Cigna typically requires prior CMA (and targeted testing when a specific disorder is suspected). The patient had a nondiagnostic chromosomal microarray, satisfying the required prior CMA; no specific additional prior single-gene test was documented as clearly indicated by the phenotype.",No,"Cigna's criteria consider a relevant family history (affected relatives with similar phenotype or consanguinity) as supportive. The only family history reported is a mother with breast cancer at 50, which is not relevant to choanal atresia or the indication for WES.",Yes,"Cigna requires documentation of pre-test genetic counseling/informed consent for broad genomic testing; the patient has seen a genetic counselor multiple times, meeting this counseling requirement.",81415,"The requested test is whole-exome sequencing (proband/or single exome), which maps to CPT code 81415.",No,"Although prior CMA and genetic counseling are documented and no age/provider exclusions apply, the patient does not meet Cigna's defined medical necessity criteria for WES (no developmental delay, progressive neurologic disorder, or multiple congenital anomalies). Therefore WES would not be covered under the payer's standard medical necessity criteria.",1964,1629,3593
Case5885,baseline,without_policy,iter2,WGS,The clinical note explicitly states 'whole genome sequencing (WGS) is requested to investigate an underlying genetic cause.',Yes,"UHC clinical sequencing policies distinguish pediatric indications and cover genomic sequencing for children with suspected genetic disorders; the patient is 11 years old, which meets pediatric age-based eligibility.",Yes,"UHC typically requires ordering by or in consultation with an appropriate specialist (geneticist/genetic counselor). Pre-test counseling was discussed with a genetic specialist, indicating the ordering/provider requirements are met.",Yes,"UHC coverage for WES/WGS includes patients with major congenital anomalies or multisystem abnormalities; the patient has a major abnormality affecting at least one organ system, which satisfies medical indication criteria.",No,"UHC policies generally require first‑tier testing (e.g., chromosomal microarray) prior to WGS/WES for many pediatric presentations. Fragile X testing was performed and nondiagnostic, but no CMA or equivalent prior test result is provided, so required prior testing appears incomplete.",No,"While a family history of long QT syndrome in the mother is reported, UHC coverage criteria for WGS emphasize family history of the same or similar phenotype to support testing. The maternal LQTS is not clearly relevant to the patient's organ‑system abnormality, so no relevant family history for eligibility is documented.",Yes,"UHC requires pre‑test genetic counseling for genomic sequencing; the record states pre‑test counseling was discussed with a genetic specialist and post‑test follow‑up plans are in place, meeting counseling requirements.",81415,The requested test is whole genome sequencing; CPT 81415 corresponds to clinical whole genome sequencing (interpretation and report).,No,"Although age, provider involvement, clinical indication, and counseling requirements are met, UHC generally requires completion of first‑tier testing (e.g., chromosomal microarray) prior to WGS for many pediatric presentations. The record does not document CMA or equivalent prior testing, so coverage is not supported until required prior testing is completed.",1975,2313,4288
Case14195,baseline,without_policy,iter2,BRCA1/2,The patient was referred specifically for BRCA1/2 testing per the clinical information.,Yes,BCBS_FEP hereditary breast/ovarian cancer testing has no exclusionary upper/lower age limit for adult testing; the patient is 18 years (adult) and therefore meets age-related eligibility.,Yes,"BCBS_FEP allows ordering by an appropriate licensed clinician (e.g., oncologist). The patient is being evaluated by an oncologist who referred for testing, satisfying ordering-provider requirements.",No,"BCBS_FEP coverage for BRCA1/2 requires relevant personal or family history of BRCA-associated cancers or a known familial pathogenic variant. This patient has no personal history of BRCA-related cancer and the family history (maternal uncle with dystonia and ataxia) is not a BRCA-related cancer history, so medical indication is not met.",Not Specified,"BCBS_FEP does not mandate specific prior genetic tests (e.g., karyotype) before BRCA1/2 testing except when a known familial variant exists; the provided info about a prior nondiagnostic karyotype is not a standard prerequisite and no specific prior-test requirement is documented.",No,BCBS_FEP requires family history of BRCA-related cancers (breast/ovarian/etc.) or a known familial pathogenic variant. The family history here (maternal uncle with dystonia and ataxia) is not relevant to BRCA eligibility and no consanguinity is reported.,No,"BCBS_FEP generally requires documented pre-test genetic counseling for hereditary cancer testing. The patient has not had pretest genetic counseling, so counseling requirements are not met.",Not Specified,"The clinical data specify BRCA1/2 testing but do not specify the exact methodology or CPT to be billed (single-gene sequencing, large panel, deletion/duplication), and multiple CPT codes may apply; therefore a single CPT cannot be determined from the provided information.",No,"Applying BCBS_FEP coverage criteria: although age and ordering provider are acceptable, the patient lacks the required medical indication (no BRCA-related personal or family cancer history) and pre-test genetic counseling is not documented. Therefore the BRCA1/2 test is not covered in this case.",1960,2490,4450
Case2847,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) is being pursued to evaluate an underlying genetic etiology.,Not Specified,BCBS FEP WES coverage policy does not impose a strict age cutoff for exome sequencing; the patient is an infant but the policy criteria are clinical rather than age-limited.,Not Specified,"BCBS FEP criteria require appropriate clinical justification and documentation and often genetic counseling, but do not strictly limit which specialist may order WES; the record shows cardiology referral plus documented genetic counseling.",Yes,Meets medical indication per BCBS FEP policy: critically ill/acute presentation (high‑risk BRUE requiring CPR) with suspicion of an underlying genetic etiology and nondiagnostic prior testing.,Yes,"BCBS FEP typically requires prior CMA for evaluation of genomic disorders; the record states prior chromosomal microarray was performed and nondiagnostic, satisfying that prerequisite.",Yes,"Family history is relevant per BCBS FEP criteria; the mother has a persistent severe immunologic/hematologic disorder, which is pertinent to evaluating a possible heritable cause.",Yes,"BCBS FEP requires pre‑test counseling for exome testing; the record documents pre‑test genetic counseling and plans for post‑test follow‑up, meeting counseling requirements.",81415,"CPT 81415 corresponds to whole exome sequencing (proband exome sequencing with interpretation), which matches the requested test.",Yes,"Under BCBS FEP coverage rules, WES is covered here: an infant with a high‑risk unexplained event suggesting a genetic etiology, nondiagnostic CMA, documented genetic counseling, and relevant family history—all criteria for medical necessity are met.",1999,1610,3609
Case11855,baseline,without_policy,iter2,CMA,The clinical note explicitly states chromosomal microarray (CMA) is being ordered to assess for copy number variants.,Not Specified,"UHC CMA coverage criteria do not impose an age cutoff for testing; the policy defines clinical indications rather than age-based eligibility, so age (14 years) is not a limiting factor per policy.",Not Specified,UHC CMA policy does not mandate a specific ordering provider specialty to authorize testing; no provider-type restriction is specified in the applicable coverage criteria.,No,"UHC medical necessity criteria for CMA require unexplained developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies. The patient has a congenital anomaly affecting a single organ system without documented global developmental delay/ID/ASD, so the specified indications are not met.",Not Specified,"UHC CMA policy does not require specific prior tests as a universal prerequisite. (Note: Fragile X testing was performed and nondiagnostic, but prior testing requirements for CMA are not defined by policy.)",Not Specified,"Family history criteria relevant to CMA coverage are not specified by UHC. The noted family history (maternal aunt with triple‑negative breast cancer) is relevant to hereditary breast cancer testing, not to CMA eligibility.",Not Specified,UHC guidance may recommend genetic counseling for genomic testing but does not list a mandatory counseling documentation requirement specific to CMA in the coverage criteria. (Pre‑test counseling was performed in this case.),81425,Chromosomal microarray testing is billed under CPT 81425 (genomic microarray/array-based copy number analysis) per standard coding used in UHC coverage/billing practices.,No,"Per UHC coverage criteria, CMA is medically necessary for developmental delay/ID/ASD or multiple congenital anomalies. The patient has a single‑organ congenital anomaly without documented developmental delay/ID/ASD, so medical necessity is not met and the test is not covered.",2011,2359,4370
Case3465,baseline,without_policy,iter2,WGS,The vignette explicitly states whole genome sequencing (WGS) has been ordered.,Yes,"UHC WES/WGS pediatric coverage criteria apply to children with unexplained developmental delay/intellectual disability; the patient is 2 years old, meeting the age‑appropriate pediatric indication.",Yes,"UHC requires ordering/oversight by a genetics provider or specialist; the test was ordered while the patient is being evaluated by a medical geneticist, meeting provider requirements.",Yes,UHC coverage criteria list unexplained developmental delay/intellectual disability without a specific syndrome as an indication for WES/WGS; the patient has developmental delay/ID without a specific syndrome.,No,"UHC generally requires prior appropriate testing (chromosomal microarray and Fragile X as first‑line) before WES/WGS. Fragile X was nondiagnostic, but there is no documentation that a chromosomal microarray (CMA) was completed.",No,"UHC criteria note relevant family history (e.g., multiple affected relatives or consanguinity) can support testing; the only family history documented is paternal Long QT syndrome, which is not a relevant family history for the patient’s neurodevelopmental indication.",Yes,"UHC requires pre‑test genetic counseling for WES/WGS; the patient had pre‑test counseling with a genetic counselor and plans for post‑test counseling, satisfying counseling requirements.",81425,CPT 81425 corresponds to whole genome sequencing (germline) which matches the ordered WGS.,No,"Although age, provider, clinical indication, and counseling meet UHC criteria, required prior testing (notably CMA) is not documented. Per UHC policy, lack of completed required prior testing means WGS is not covered at this time.",1981,1492,3473
Case15557,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) is being pursued.,Yes,"UHC WGS/WES policies focus on individuals with congenital anomalies or neurodevelopmental disorders and often include pediatric age groups; the patient is 15 years old, which meets pediatric age-based eligibility for diagnostic WGS.",Not Answerable,"UHC policies commonly require ordering or documentation by a qualified provider (eg, genetics provider) or documentation of genetics involvement; the record does not state who formally placed the WGS order, so adequacy of the ordering provider cannot be determined from provided information.",Yes,"UHC criteria support WGS for individuals with unexplained congenital anomalies/multiple congenital anomalies; the patient has a congenital anomaly present since birth, meeting a medical indication for diagnostic WGS.",No,"UHC generally requires prior appropriate testing (eg, chromosomal microarray and/or appropriate targeted tests) before WGS; only FISH was performed and was nondiagnostic, and FISH alone does not satisfy the typical prior-testing requirement (CMA) per policy.",Yes,"UHC policies consider relevant family history in support of WGS; the patient has a sibling with a similar congenital anomaly, which is a relevant family history for genetic evaluation.",Yes,"UHC typically requires pre- and post-test genetic counseling or documentation of genetics involvement; the patient has been seen multiple times by a genetic counselor with plans for post-test counseling, satisfying counseling requirements.",81425,The requested test is whole genome sequencing; CPT code 81425 corresponds to genome sequencing services and best matches WGS.,No,"Although age, medical indication, family history, and genetic counseling are met, required prior testing (eg, chromosomal microarray) has not been completed per UHC coverage rules; lacking required prior tests makes the WGS request non-covered at this time.",1978,1830,3808
Case4982,baseline,without_policy,iter2,WES,The clinical note explicitly states the patient is being considered for whole exome sequencing (WES).,Yes,UHC policies allow WES for pediatric patients with unexplained neurodevelopmental or syndromic presentations; an 11-year-old meets pediatric age-related eligibility for WES.,Yes,Ordering by a developmental pediatrician with documented genetic counselor involvement meets typical UHC ordering/provider requirements for genetic testing referral and authorization.,Yes,Clinical indications—Hirschsprung disease with developmental evaluation plus a sibling with early-onset epileptic encephalopathy—are consistent with UHC medical necessity criteria for WES to evaluate a suspected heritable syndromic/neurodevelopmental condition.,No,"UHC commonly requires prior standard testing (e.g., chromosomal microarray) for neurodevelopmental indications; the patient had FISH (nondiagnostic) but no documentation of prior CMA, so required prior testing was not completed.",Yes,The patient has a sibling with epileptic encephalopathy before age three—family history relevant to suspicion of a heritable disorder and consistent with family-history criteria in coverage guidelines.,Yes,"The family has met with a genetic counselor multiple times for pre-test counseling with planned post-test disclosure, satisfying UHC counseling requirements for WES.",81415,CPT 81415 corresponds to clinical whole exome sequencing and is the appropriate billing code for the requested WES.,No,"Although age, provider, indication, family history, and counseling criteria are met, required prior testing (notably chromosomal microarray) was not documented as completed; per UHC coverage criteria the absence of required prior testing makes WES not covered at this time.",2007,1542,3549
Case14371,baseline,without_policy,iter2,WES,The clinical note explicitly states the general pediatrician ordered whole exome sequencing (WES).,Not Specified,UHC WES coverage criteria are applied to pediatric and adult patients and do not impose a strict age cutoff; the patient is 11 years old but the policy does not specify an age-based exclusion.,Not Specified,"UHC typically requires an appropriate ordering clinician but does not universally restrict WES orders to medical geneticists only; the record shows a general pediatrician ordered testing, and the policy does not explicitly prohibit this.",Yes,"UHC coverage criteria for WES include unexplained neurodevelopmental disorders/ASD and developmental delay/intellectual disability. The patient has a complex neurodevelopmental disorder and autism spectrum disorder, fulfilling a defined clinical indication.",No,"UHC generally requires prior first‑line testing for developmental disorders (commonly chromosomal microarray and Fragile X when indicated). Fragile X was nondiagnostic, but there is no documentation that chromosomal microarray (CMA) was completed, so required prior testing is incomplete.",Not Specified,"While family history (here a maternal aunt with severe immunologic disorder) may be relevant clinically, UHC WES eligibility criteria do not make a specific family history or consanguinity requirement for coverage; therefore family history is not a specified eligibility criterion.",Yes,"UHC WES policies typically require pre‑test genetic counseling and documentation. The family met with a genetic counselor before testing and planned post‑test follow‑up, meeting that counseling requirement.",81415,CPT 81415 corresponds to exome sequencing (WES) for the proband with sequence analysis and interpretation and is the appropriate code for the requested WES.,No,"Although the patient meets clinical indications and has pre‑test genetic counseling and Fragile X testing, UHC requires completion of specified prior testing (e.g., CMA) before WES for developmental/neurodevelopmental indications; CMA is not documented, so coverage would not be approved at this time.",1983,1674,3657
Case15202,baseline,without_policy,iter2,BRCA1/2,The clinical note states she was referred for BRCA1 and BRCA2 testing to evaluate hereditary breast/ovarian cancer risk.,No,"BCBS_FEP BRCA coverage criteria include age/onset-based rules (e.g., breast cancer diagnosed at young age ≤50 or other early-onset criteria). The patient is 65 and her tumor is a malignant phyllodes (a stromal tumor), so she does not meet the age/onset-related eligibility in the policy.",Yes,"BCBS_FEP requires documentation of appropriate ordering and genetic counseling; the record documents pre-test counseling with a genetic specialist and a referring physician (gynecologist), which satisfies ordering/counseling/provider requirements.",No,"Policy medical indications for BRCA testing are personal history of epithelial breast cancer (especially early-onset, triple-negative ≤60, bilateral/multiple primaries), ovarian cancer, or qualifying family history. A malignant phyllodes tumor and a sister with an immunologic/hematologic disorder do not meet those clinical criteria.",Not Specified,BCBS_FEP does not generally require prior diagnostic genetic tests before BRCA1/2 unless a known familial BRCA variant exists; no such prior BRCA-family testing requirement is documented here.,No,BCBS_FEP family-history criteria specify relatives with breast/ovarian/pancreatic/prostate cancers or known BRCA mutation. The sister's reported immunologic/hematologic disorder is not a qualifying family history for BRCA testing.,Yes,"BCBS_FEP expects pre-test genetic counseling for hereditary cancer testing. The patient completed pre-test counseling with a genetic specialist and has planned post-test follow-up, meeting counseling requirements.",81162,"The requested test is BRCA1/BRCA2 germline testing; among the provided CPT choices, 81162 corresponds to BRCA1/BRCA2 testing (gene-specific hereditary breast/ovarian cancer testing).",No,"Applying BCBS_FEP BRCA coverage criteria: although counseling and ordering requirements are met, the patient lacks qualifying personal (epithelial breast/ovarian) or family history indications and does not meet age/onset criteria; therefore BRCA testing is not covered in this situation.",1990,2612,4602
Case8621,baseline,without_policy,iter2,WES,The patient is explicitly undergoing whole exome sequencing (WES) per the clinical information.,Not Specified,UHC WES coverage is driven by clinical presentation (pediatric neurodevelopmental disorder) rather than a strict age cutoff; no specific age-exclusion is stated and a 2-year-old is within typical pediatric indications.,Not Specified,"UHC policies generally require appropriate documentation and genetics involvement but do not universally limit ordering to a single specialty; the record shows an oncologist ordered the test and genetics counseling was completed, and the policy does not strictly specify that the ordering provider must be a geneticist.",Yes,"UHC covers WES for individuals with unexplained global developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies; this 2‑year‑old has a complex neurodevelopmental disorder with autism and prior nondiagnostic CMA, meeting clinical indications.",Not Answerable,"UHC typically requires prior chromosomal microarray (CMA) and, when indicated, targeted testing (e.g., Fragile X in males). The patient has a nondiagnostic CMA, but the chart does not state the child’s sex or whether Fragile X or other indicated targeted testing was completed, so completeness of all required prior tests cannot be determined.",Not Specified,"Although the family reports an uncle with a congenital anomaly, UHC WES criteria do not generally require a specific family history/consanguinity to authorize WES; family history is supportive but not a defined eligibility requirement in the policy.",Yes,"UHC requires documentation of pre‑test genetic counseling for clinical WES; the family reports multiple genetic counseling visits with pre‑test counseling completed and plans for post‑test follow‑up, meeting this requirement.",81415,"CPT 81415 corresponds to exome sequencing (proband only). The request documents WES for the child only (no trio indicated), so 81415 is the appropriate code.",Yes,"Clinical indications (pediatric autism/neurodevelopmental disorder), prior nondiagnostic CMA, and documented pre‑test genetic counseling align with UHC WES coverage criteria; no explicit disqualifying factors are present in the provided information.",1988,2027,4015
Case14141,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) is planned to investigate an underlying genetic etiology.,Not Specified,"FEP WES coverage criteria are based on clinical presentation (e.g., unexplained developmental delay, congenital anomalies) rather than a strict age cutoff; the patient is pediatric (7 years) but no specific age limit is specified in the policy.",Not Specified,"FEP medical policy requires an appropriate ordering/qualified provider and documentation (including counseling) but does not mandate a single specific specialty; the information shows referral by an oncologist which is an appropriate treating specialist, but the policy does not specify a single required provider type.",Yes,"FEP WES coverage supports testing for unexplained multiple congenital anomalies and global developmental delay/intellectual disability; this patient has multiple congenital anomalies, prior nondiagnostic CMA, and family history of developmental delay, meeting the clinical indication criteria.",Yes,FEP policy for WES generally requires prior chromosomal microarray as first-tier testing for developmental delay/ congenital anomalies; the record states CMA was performed and reported nondiagnostic.,Yes,"Family history is relevant under FEP criteria when there is a similarly affected relative; the patient has a sibling with global developmental delay, which supports testing.",Yes,FEP requires pre-test genetic counseling and arrangements for post-test counseling for WES; the record documents pre-test counseling and plans for post-test follow-up.,81415,"CPT 81415 corresponds to exome sequencing (proband only), which matches the requested whole exome sequencing.",Yes,"Under FEP criteria, WES is covered for patients with unexplained multiple congenital anomalies and developmental delay when prior CMA is nondiagnostic, genetic counseling is completed, and there is relevant family history; all those elements are documented for this 7-year-old patient.",1983,1762,3745
Case6747,baseline,without_policy,iter2,WGS,The patient is undergoing whole genome sequencing (WGS) per the clinical information.,Not Specified,BCBS_FEP WGS coverage criteria do not impose a specific age cut‑off for diagnostic WGS in symptomatic patients; the patient is 12 years old and no age restriction is specified.,Yes,"BCBS_FEP policies require ordering by an appropriate specialist (medical geneticist or clinician with genetics expertise) for complex genomic testing; the test was ordered by a medical geneticist, meeting provider requirements.",Yes,"Clinical indications in BCBS_FEP for WGS include unexplained multiple congenital anomalies/developmental delay/intellectual disability when prior testing is nondiagnostic. The patient has multiple congenital anomalies and a suspected genetic etiology, meeting medical indication.",Yes,"BCBS_FEP typically requires prior standard testing such as chromosomal microarray before WES/WGS for developmental anomalies; CMA was previously performed and was nondiagnostic, satisfying prior-test requirements.",Yes,"Family history/recurrence (sibling with developmental delay) is relevant to genomic testing eligibility per payer criteria and is present in this case, supporting testing (including potential trio analysis).",Yes,"BCBS_FEP requires documentation of genetic counseling for germline genomic testing; pre-test counseling was completed and post-test counseling is planned, meeting counseling requirements.",81425,CPT 81425 corresponds to clinical genome sequencing (WGS) and is the appropriate billing code for the requested WGS.,Yes,"All applicable BCBS_FEP coverage criteria are met: appropriate clinical indication (multiple congenital anomalies), prior CMA nondiagnostic, ordering provider is a medical geneticist, family history supportive, and genetic counseling documented; therefore WGS is covered.",1966,1674,3640
Case811,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) is being pursued.,Not Specified,BCBS_FEP WES criteria are based on clinical indications (congenital anomalies/early neurologic disorder) rather than a strict age cutoff; no specific age limitation is specified that would exclude a 7‑week‑old.,Yes,"BCBS_FEP allows ordering by the treating/ordering physician; the case was referred by a general pediatrician and testing is being ordered through the treating team, which meets payer ordering provider requirements.",Yes,"Patient has early‑onset movement disorder (dystonia, ataxia, intermittent hemiplegia) and a positive family history plus nondiagnostic CMA — these are BCBS_FEP‑recognized indications for WES to evaluate an underlying genetic etiology.",Yes,"BCBS_FEP requires prior chromosomal microarray for many presentations; CMA was previously performed and reported as nondiagnostic, satisfying required prior testing.",Yes,"There is a relevant family history: an older sibling with multiple congenital anomalies, which supports testing per BCBS_FEP family‑history considerations.",Yes,"Pre‑test counseling was completed with a genetic counselor, meeting BCBS_FEP counseling requirements for WES.",81415,CPT 81415 corresponds to clinical exome (WES) sequence analysis and is the appropriate code for the requested test.,Yes,"Under BCBS_FEP criteria the infant meets medical‑necessity indications (early severe neurologic/movement disorder), had required prior CMA testing nondiagnostic, has relevant family history, and completed genetic counseling — therefore WES is covered.",2018,1981,3999
Case7604,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been ordered to evaluate an underlying genetic etiology.,Not Specified,UHC WGS/WES coverage criteria are applied to clinical indication rather than limiting by neonate vs older child in this scenario; no specific age cutoff is provided in the patient documentation.,Not Specified,"UHC generally requires an appropriate ordering clinician, but the payer policy does not strictly restrict ordering to a geneticist in all cases. The record shows a neurologist ordered testing; the policy does not explicitly prohibit this, so ordering-provider specificity is not clearly specified in the documentation.",Yes,"UHC coverage criteria support WGS/WES for individuals with multiple congenital anomalies or multisystem involvement when genetic etiology is suspected; the neonate has multiple congenital anomalies affecting several organ systems, meeting the clinical indication.",No,"UHC policy typically requires prior first‑tier cytogenetic testing such as chromosomal microarray (CMA) before WGS/WES for multiple congenital anomalies. Only FISH was done (nondiagnostic); CMA was not documented, so required prior testing is incomplete.",Yes,The patient has an affected older sibling with multiple congenital anomalies; family history is documented and is relevant under UHC criteria as supporting the genetic evaluation.,No,"UHC normally requires documentation that pre‑test genetic counseling was offered/occurred for complex genomic testing. The family explicitly declined genetic counseling, so counseling requirements are not met.",81415,The test ordered is whole genome sequencing; CPT 81415 corresponds to whole genome sequence analysis in standard CPT mappings used for payer adjudication.,No,"Although clinical indication (multiple congenital anomalies, positive family history) supports WGS, coverage requirements (documentation of prior appropriate testing — CMA — and completed pre‑test genetic counseling) are not met per UHC criteria; therefore the test is not covered as submitted.",1973,1840,3813
Case950,baseline,without_policy,iter2,WES,Patient record explicitly states whole exome sequencing (WES) is being pursued to look for an underlying genetic cause of early-onset epileptic encephalopathy.,Not Specified,UHC WES/WGS policies are driven by clinical phenotype rather than strict patient age limits; the chart documents disease onset before age 3 but no payer age restriction is specified for WES in this context.,Yes,"UHC typically requires ordering/authorization by an appropriate specialist (medical geneticist or other qualified clinician) for WES; the test is being ordered in the setting of evaluation by a medical geneticist, meeting that provider requirement.",Yes,"UHC clinical indications for WES include unexplained, likely genetic neurologic disorders such as early-onset epileptic encephalopathy; the patient has unexplained epileptic encephalopathy with onset <3 years, which meets a defined medical indication.",No,"UHC generally expects prior targeted testing (for epilepsy: an epilepsy multigene panel) and/or prior cytogenomic testing (eg, chromosomal microarray) to be performed or documented as nondiagnostic before WES; the record states no prior epilepsy multigene panel and only a nondiagnostic karyotype (not CMA), so required prior testing has not been completed.",No,Family history cited (an uncle with high‑risk prostate cancer) is not a relevant family history for eligibility for WES for epileptic encephalopathy and there is no reported family history of similar neurologic disorder or consanguinity.,Yes,"UHC requires documentation of genetic counseling for WES; the patient has had multiple pre‑test genetic counseling visits and plans are in place for post‑test counseling, satisfying counseling requirements.",81415,CPT 81415 corresponds to exome sequencing (proband) diagnostic testing and is the appropriate code for clinical WES.,No,"Although the patient meets clinical indication and provider/counseling requirements, UHC coverage generally requires prior targeted epilepsy gene panel and/or appropriate cytogenomic testing (eg, CMA) to be nondiagnostic before WES. Required prior testing has not been completed (no epilepsy panel, CMA not documented), so per payer criteria the WES request would not be covered as submitted.",2012,1911,3923
Case17822,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been ordered as the next‑tier diagnostic test.,Not Specified,UHC WES/WGS coverage criteria are driven by clinical indication rather than strict age cutoffs; no payer age restriction is specified and a 13‑year‑old is a typical pediatric candidate.,Yes,"UHC requires ordering by an appropriate genetics provider or clinician experienced in genetics for WES/WGS; the order was placed by a medical geneticist, which meets that requirement.",Yes,UHC covers WES/WGS for individuals with multiple congenital anomalies or complex multisystem presentations after nondiagnostic CMA; the patient has multisystem congenital anomalies and meets that clinical indication.,Yes,UHC generally requires prior chromosomal microarray (CMA) to be nondiagnostic before WGS; the record states a nondiagnostic CMA was performed.,Not Specified,"Although a sibling with short stature is reported, UHC WGS criteria do not generally require positive family history/consanguinity as a prerequisite for coverage in this clinical scenario, so family history is not a specified gating criterion here.",No,"UHC typically requires documented pre‑test genetic counseling/consent for clinical WES/WGS. The family declined counseling prior to testing, so the counseling requirement is not met.",81425,"Among the provided CPT options, 81425 corresponds to whole genome sequencing (WGS) analysis and reporting.",No,"Although the patient meets clinical indication, age is appropriate, a nondiagnostic CMA was completed, and the order was placed by a medical geneticist, documented pre‑test genetic counseling (a UHC coverage requirement) was declined. Failure to meet the counseling requirement means the test would not meet all UHC coverage conditions.",1985,2199,4184
Case9408,baseline,without_policy,iter2,WES,The patient information explicitly states the patient is undergoing whole exome sequencing (WES) ordered by a medical geneticist for evaluation of epileptic encephalopathy.,Not Specified,"FEP WES coverage criteria do not impose a strict age cutoff for WES; eligibility is driven by clinical indication (early-onset epileptic encephalopathy) rather than a specific age limit, so age-based criteria are not specified.",Yes,"FEP requires an appropriate ordering clinician (e.g., medical geneticist or relevant specialist) for WES; the order was placed by a medical geneticist, satisfying provider requirements.",Yes,FEP considers WES medically indicated for unexplained early-onset epileptic encephalopathy (onset <3 years) as a recognized indication; the patient has epileptic encephalopathy with onset before three years.,Yes,"FEP typically requires prior first‑tier testing such as chromosomal microarray before WES for neurodevelopmental/epileptic presentations; the patient had CMA previously performed and nondiagnostic, meeting prior test requirements.",Not Specified,"FEP WES coverage is driven by the proband's clinical presentation and prior testing rather than requiring specific family history or consanguinity; while a maternal hematologic/immunologic disorder is noted, family history criteria are not specified as a requirement.",Yes,FEP policy requires documentation of pre‑test genetic counseling and plans for post‑test follow‑up for WES; the record states pre‑test counseling was completed and post‑test follow‑up with a genetic counselor is planned.,81415,CPT 81415 corresponds to whole exome sequencing (sequence analysis and interpretation) and is the appropriate code for the requested WES.,Yes,"Under FEP criteria the patient meets clinical indication (early-onset epileptic encephalopathy), prior required testing (nondiagnostic CMA) is documented, the order is from a medical geneticist, and genetic counseling was completed—therefore WES is covered.",1998,2312,4310
Case3592,baseline,without_policy,iter2,CMA,The case explicitly states 'chromosomal microarray (CMA) testing for developmental disorders is being requested.',Not Specified,CMA coverage criteria are not typically age‑limited and the provided information does not indicate a payer age restriction for CMA; neonatal status does not conflict with usual CMA indications.,Not Specified,"The information does not identify any Cigna requirement that only a specific provider type must order CMA; additionally the record notes involvement of a developmental pediatrician and genetic specialist for counseling, which meets usual practice expectations.",Yes,"CMA is a recognized test for unexplained neurodevelopmental disorders/encephalopathy. The neonate has unexplained epileptic encephalopathy with neonatal onset, which meets standard medical indication criteria for CMA under developmental/neurologic disorder indications.",Not Specified,"There are no specific prior testing requirements for ordering CMA in the provided criteria. Although a prior CMA was nondiagnostic, the policy does not uniformly require other tests be completed before repeat CMA (requirements vary by circumstance).",Yes,"Patient has relevant family history: an older sibling with unexplained developmental regression, which supports a hereditary/genetic etiology and is clinically relevant for eligibility considerations.",Not Specified,"While genetic counseling is recommended for cytogenomic testing and the record documents pre‑test discussion with a genetic specialist and planned post‑test follow‑up, explicit payer‑mandated counseling requirements for CMA are not specified in the provided criteria.",81228,"CPT 81228 corresponds to chromosomal microarray/constitutional microarray testing (CMA), which matches the requested test.",No,"Although the clinical indication (neonatal unexplained epileptic encephalopathy) supports genetic testing, Cigna policies generally cover CMA as a first‑line test once for developmental disorders; a prior CMA was nondiagnostic and repeat CMA is usually not covered unless there are new clinical findings, a change in testing technology/platform, or other justification. The record notes no prior epilepsy multigene panel or other new-test justification that would support repeating the same CMA; therefore coverage would be denied under standard Cigna repeat‑testing rules.",1990,2399,4389
Case17929,baseline,without_policy,iter2,CMA,The referral explicitly states 'tumor chromosomal microarray (CMA) testing has been requested' to assess for genomic imbalance.,Not Specified,"UHC CMA coverage criteria focus on clinical presentation (congenital/major anomalies, developmental delay, autism) rather than strict age cutoffs; the record shows a 7-year-old but no age-based exclusion or specific age requirement is stated.",Not Specified,UHC policy does not mandate a specific ordering provider specialty for CMA (orders may come from treating specialists/genetics); the case was referred by a neurologist which is acceptable but no payer-specific specialty requirement is documented.,Yes,"UHC covers CMA for individuals with major congenital anomalies or abnormalities affecting organ systems; the child has a major abnormality affecting at least one organ system, meeting a defined clinical indication.",Yes,"Payer criteria often require prior karyotype when indicated or note CMA after nondiagnostic karyotype; the record documents a prior nondiagnostic karyotype, satisfying prior test requirements.",No,"Family history noted is BRCA1/2 pathogenic variants in mother/aunt, which is not relevant to CMA eligibility (CMA assesses copy-number/genomic imbalance), so no relevant family/consanguinity criterion is present.",Yes,"UHC commonly expects documentation of pre-test genetic counseling for genomic testing; the record documents multiple pretest counseling sessions with a genetic counselor and planned post-test follow-up, meeting counseling requirements.",81425,CPT 81425 corresponds to chromosomal microarray/genome-wide copy-number analysis commonly billed for CMA testing.,Yes,"Based on UHC coverage criteria: the child meets a covered clinical indication (major congenital/organ system abnormality), prior karyotype was nondiagnostic, counseling documented, and no disqualifying factors are present; therefore CMA is covered.",1994,1763,3757
Case12834,baseline,without_policy,iter2,CMA,Requisition and ordering note specify chromosomal microarray testing (CMA) despite tumor-type assay being selected; patient was referred for evaluation of a complex neurodevelopmental disorder and CMA was ordered.,Not Specified,Cigna's CMA coverage criteria are indication-based (developmental delay/intellectual disability/ASD/multiple congenital anomalies) rather than age-limited; the 16-year-old falls within typical pediatric/adolescent scope but no explicit age cutoff is specified in the policy.,Not Specified,"Cigna's CMA policy does not mandate a specific ordering provider specialty; the test was ordered by a developmental pediatrician which is appropriate, but the policy does not impose explicit provider-type requirements.",Yes,"Cigna considers CMA medically necessary as a first-line test for individuals with unexplained developmental delay/intellectual disability/ASD or multiple congenital anomalies. The patient has a complex neurodevelopmental disorder affecting at least one organ system, meeting the medical indication.",Not Specified,Cigna's CMA coverage is indication-driven and does not universally require specific prior genetic tests; Fragile X testing was already nondiagnostic (documented) but the policy does not mandate prior testing as a prerequisite for CMA.,Not Specified,"CMA coverage is based on the patient's clinical presentation; although there is a maternal uncle with dystonia/ataxia, Cigna's CMA criteria do not hinge on family history/consanguinity as a requirement.",Not Specified,Cigna's coverage criteria for CMA do not explicitly require documented genetic counseling as a condition of coverage; genetic counseling is not documented in the record but policy does not make this a coverage prerequisite.,81228,"CPT 81228 corresponds to chromosomal microarray (copy number analysis), which matches the requested CMA test.",Yes,"Per Cigna coverage policy, CMA is medically necessary for individuals with unexplained developmental delay/intellectual disability/ASD or multiple congenital anomalies. The 16-year-old has a complex neurodevelopmental disorder and prior Fragile X testing was nondiagnostic, so CMA meets coverage criteria.",1991,1745,3736
Case4604,baseline,without_policy,iter2,WES,The narrative explicitly states whole exome sequencing (WES) is being requested.,Not Specified,BCBS_FEP WES policy does not impose a strict age cutoff for WES in unexplained developmental delay/intellectual disability; the patient is 6 years old which is an appropriate pediatric age but the payer criteria do not specify an age limit.,Not Specified,"The case notes a PCP referral and that pre-test counseling was completed by a genetic counselor, but the provided information and typical BCBS_FEP wording do not mandate a specific ordering provider specialty in this scenario.",Yes,"BCBS_FEP coverage criteria support WES for unexplained developmental delay/intellectual disability after prior first-tier testing is nondiagnostic; the patient has developmental delay/intellectual disability with no specific syndrome suspected and CMA was nondiagnostic, meeting medical indication criteria.",Yes,"BCBS_FEP typically requires prior chromosomal microarray as first‑tier testing for unexplained DD/ID; the record states CMA was performed and nondiagnostic, satisfying the required prior test. (Fragile X testing can be recommended in some contexts, particularly males, but CMA is the primary required prior test documented as completed.)",Yes,"The family reports an older sibling with moderate–severe intellectual disability, which is relevant family history that supports genetic evaluation per BCBS_FEP criteria.",Yes,"BCBS_FEP WES policy expects documentation of pre‑test genetic counseling; the case documents pre‑test counseling by a genetic counselor and plans for post‑test follow up, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical exome (whole exome) sequencing, which best matches the requested WES.",Yes,"Under BCBS_FEP criteria WES is covered for unexplained developmental delay/intellectual disability after nondiagnostic CMA; the patient meets medical indication, required prior CMA was nondiagnostic, genetic counseling documented, and relevant family history is present, supporting coverage.",1995,2300,4295
Case8661,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) is requested.,Yes,UnitedHealthcare WES/WGS criteria specify pediatric eligibility for suspected genetic disorders; the patient is 7 years old (meets pediatric age criteria).,Not Specified,"The record shows the ordering provider is the child's neurologist. UHC coverage policies do not universally mandate a single specific specialty as the only permitted ordering provider in this scenario (ordering by an appropriate specialist is acceptable), and no explicit provider-restriction is documented in the provided patient information.",Yes,"UHC medical necessity criteria include children with unexplained sensory impairment, possible neurodevelopmental disorder and/or early-onset epileptic presentations in the family; the patient has childhood hearing/visual impairment and a sibling with early epileptic encephalopathy, meeting clinical indications.",No,"UHC generally requires prior appropriate testing (e.g., chromosomal microarray) before WES/WGS; only Fragile X testing was reported (nondiagnostic) and no CMA/other required prior test is documented.",Yes,"The patient has a relevant family history (sibling with epileptic encephalopathy before age 3), which is a specified family-history criterion supporting testing under UHC policy.",No,"UHC policies typically require documented pre-test genetic counseling for WES/WGS; counseling was offered but the family declined pre-test counseling, so the counseling requirement is not met.",81425,Whole genome sequencing is reported using CPT code 81425 (WGS).,No,"Although the patient meets clinical indications and age criteria, coverage prerequisites per UHC (documented prior testing such as CMA and documented pre-test genetic counseling) are not satisfied; therefore WGS is not covered at this time.",2001,1811,3812
Case6451,baseline,without_policy,iter2,WGS,The clinical note explicitly states 'whole genome sequencing (WGS) is being pursued.',Not Specified,UHC WES/WGS policies define clinical indications rather than a strict age cutoff; no payer-specific absolute age exclusion is stated for WGS in this clinical context and the infant age does not conflict with typical pediatric eligibility.,Not Specified,"UHC generally requires an appropriate ordering clinician and documentation of counseling but does not mandate a single specific specialty; the record lists a developmental pediatrician ordering the test (an appropriate clinician), but the policy does not impose a narrowly defined provider-type requirement.",Yes,"The infant has significant unexplained hypotonia in the neonatal period, which meets UHC clinical indications for WES/WGS for suspected genetic disorders (unexplained neurodevelopmental/neuromuscular findings).",No,"UHC typically requires prior chromosomal microarray (CMA) for unexplained developmental/neurogenic presentations; the record notes a nondiagnostic karyotype but does not document a prior CMA, so the required prior test was not completed.",No,"While a maternal history of a severe immunologic/hematologic disorder is reported, it is nonspecific and not documented as a similarly affected relative or known familial variant; UHC family-history criteria require a relevant/similar affected relative or known familial pathogenic variant.",Yes,"The chart documents that pre-test counseling was completed and post-test genetics follow-up is planned, meeting UHC requirements for documented genetic counseling/informed consent for WGS.",81425,81425 is the CPT code corresponding to whole genome sequencing (WGS) interpretation and report.,No,"Although the indication (infant hypotonia) and counseling meet UHC clinical criteria, UHC requires prior CMA for unexplained developmental/neuro presentations and no CMA is documented; absence of the required prior testing makes the WGS noncovered at this time.",1975,2096,4071
Case19255,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states the patient was referred for BRCA1/2 testing to evaluate hereditary breast/ovarian cancer predisposition.,Not Specified,"No payer-specific age cutoff is provided in the patient data. UnitedHealthcare policies use clinical criteria (e.g., personal/family history, multiple primaries) rather than a strict single age limit for BRCA testing in many situations; the record gives the patient’s age (38) but does not provide policy text with specific age-based thresholds.",Not Specified,"The record notes referral by a neurologist and that pre-test counseling was completed by a genetic specialist, but it does not explicitly identify the ordering provider. UHC may require an ordering clinician or documented genetic counseling; available data do not state who will place the test order.",Yes,"Per UHC BRCA coverage criteria, a personal history of multiple (separate primary) breast cancers meets medical indication for BRCA1/2 testing. The patient has two separate primary breast cancers, satisfying that clinical criterion.",Not Specified,"The chart notes prior FISH testing was nondiagnostic, but UHC BRCA criteria do not generally mandate a specific prior genetic test before BRCA sequencing for a patient with a qualifying personal history; no required prior tests are documented.",Yes,Family history includes a father with metastatic prostate cancer. UHC criteria count relevant family history of prostate cancer (particularly metastatic/early-onset) as supporting evidence for BRCA2-related testing; thus a relevant family history is present.,Yes,"UHC typically requires or expects documentation of pre-test genetic counseling for BRCA testing. The record states pre-test counseling was completed with a genetic specialist, meeting counseling requirements.",81162,"Of the provided CPT options, 81162 corresponds to BRCA1/BRCA2 large rearrangement (deletion/duplication) analysis and is the closest specific BRCA-related CPT among the listed choices; full BRCA sequencing CPTs (81211/81212) are not provided.",Yes,"Based on UHC coverage criteria: the patient has a qualifying personal history (two separate primary breast cancers), relevant family history (father with metastatic prostate cancer), and documented pre-test genetic counseling. These factors meet medical necessity and counseling requirements for BRCA1/2 testing, so the test is covered.",1972,2185,4157
Case2211,baseline,without_policy,iter2,BRCA1/2,The referral explicitly requests BRCA1 and BRCA2 (breast cancer susceptibility) testing.,Yes,"Payer criteria permit BRCA testing for adults and include scenarios with a known familial pathogenic BRCA variant; the patient is a 21‑year‑old adult, meeting age requirements under UHC familial/clinical BRCA criteria.",Yes,"UHC typically requires an ordering clinician and documentation of genetic counseling; the test was ordered by a clinician with pre‑test counseling completed by a genetics specialist, satisfying provider/counseling requirements.",Yes,"Clinical indications in the payer policy include a known familial BRCA pathogenic variant and multiple affected relatives; the patient’s mother is a known BRCA2 pathogenic variant carrier and there are ≥2 affected relatives, so the patient meets medical indication.",Yes,"When a familial BRCA pathogenic variant exists, prior testing of the affected relative is the required prior test; the patient reports the mother carries a known BRCA2 pathogenic variant, so prior testing requirement is met.",Yes,"Family history criteria are relevant for BRCA testing; patient reports ≥2 additional affected blood relatives on same side and a mother with a known BRCA2 pathogenic variant, which is directly relevant to eligibility.",Yes,"UHC requires documentation of pre‑test genetic counseling for BRCA testing; the patient had pre‑test counseling with a genetic specialist and plans post‑test follow‑up, meeting counseling requirements.",81162,The most appropriate CPT among the provided options for BRCA targeted/familial BRCA testing is 81162 (targeted familial variant analysis for BRCA1/2) given the known family BRCA2 pathogenic variant.,Yes,"Under UHC BRCA coverage criteria the combination of a known familial BRCA2 pathogenic variant, the patient’s personal/family cancer history, adult age, and documented pre‑test counseling satisfies coverage requirements.",2000,2032,4032
Case18882,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested.,Not Specified,UHC genomic sequencing policies do not impose a strict age cutoff for WES; the patient is 8 years old which is an appropriate pediatric age but the policy does not specify age-based exclusion or special age-based criteria.,Not Specified,"UHC policy does not mandate a single specific ordering provider type (e.g., only geneticists) for WES in most cases; no provider specialty restriction is documented in the provided information.",Yes,"UHC medical necessity criteria for WES include unexplained multiple congenital anomalies or multisystem findings/developmental concerns; this 8‑year‑old has multiple congenital anomalies affecting several organ systems, meeting a defined clinical indication.",No,"UHC generally requires prior appropriate first‑tier testing (e.g., chromosomal microarray) for developmental delay/multiple congenital anomalies; the record documents only nondiagnostic FISH and does not document prior CMA, so required prior testing has not been completed.",Not Specified,"Although the family reports a maternal history of long QT syndrome, UHC WES coverage criteria do not specify family history/consanguinity as a required criterion in this scenario; the policy does not make family history a gating requirement here.",No,"UHC and typical genomic sequencing policies require pre‑test genetic counseling (or documented counseling consent) prior to WES; the family declined pre‑test counseling and only agreed to post‑test counseling, so counseling requirements are not met.",81415,CPT 81415 is the appropriate code for whole exome sequencing (exome sequencing with interpretation and report).,No,"Although the patient meets a clinical indication for WES (multisystem congenital anomalies), UHC coverage requires prior appropriate testing (e.g., CMA) and pre‑test genetic counseling; both requirements are not met (no documented CMA and pre‑test counseling declined), so the test is not covered as presented.",1978,1796,3774
Case14408,baseline,without_policy,iter2,BRCA1/2,The referral explicitly requests BRCA1/2 testing for this patient (stated in the patient information).,Not Specified,Cigna BRCA policies do not impose a strict absolute age cutoff for BRCA testing; age-based limits are defined for certain affected-case indications but there is no general age exclusion that would bar testing at age 75.,Not Specified,Cigna policies typically do not mandate a specific ordering provider specialty for BRCA testing (beyond documentation of pre-test counseling); the record shows referral from family medicine but the policy does not explicitly restrict ordering to genetics specialists.,Yes,"Per Cigna clinical criteria, a first-degree relative with BRCA-associated cancer (male breast cancer) constitutes a relevant clinical indication for BRCA testing. The patient has a brother with breast cancer, which meets a defined BRCA-associated family-history criterion (regardless of prior-test sequencing requirements).",No,"Cigna's coverage practice requires that an affected family member who meets testing criteria be tested first when available. There is no prior genetic testing of the affected brother documented, so the required prior test has not been completed.",Yes,"The patient has a documented first-degree family history (brother) of breast cancer, which is directly relevant to BRCA testing eligibility per Cigna criteria.",Yes,"Cigna requires documentation of genetic counseling for BRCA testing; the patient information states that pre-test counseling was completed and post-test follow-up with a genetic counselor is planned, satisfying counseling requirements.",81277,"Of the provided CPT options, 81277 is the code that best corresponds to multi-gene/single-gene BRCA1/2 sequencing/analysis as used for BRCA1/2 testing in payer billing mappings.",No,"Although the patient meets a clinical indication (first-degree relative with male breast cancer) and counseling is documented, Cigna policy requires that the affected relative who meets testing criteria be tested first when available. There is no documentation that the affected brother has been tested or is unavailable for testing, so coverage would be denied until required prior testing of the affected family member is completed.",1957,2973,4930
Case4262,baseline,without_policy,iter2,WES,The clinical note explicitly states the infant was referred for diagnostic whole exome sequencing (WES).,Not Specified,BCBS_FEP WES policy does not impose a strict single age cutoff in typical language — WES indications are phenotype-driven (pediatric patients commonly included) — no age restriction is documented that would exclude a 5‑week‑old.,Yes,"BCBS_FEP generally requires ordering by a treating clinician or genetics provider and documentation of counseling/indication; the test was ordered via the patient's treating specialist (oncologist) and pre‑test genetic counseling is documented, satisfying provider/counseling requirements.",Yes,"BCBS_FEP criteria list unexplained multiple congenital anomalies that do not fit a well‑delineated syndrome as a covered indication for WES; the infant has multiple congenital anomalies and prior testing (karyotype) was nondiagnostic, meeting the clinical indication.",No,"BCBS_FEP WES policy requires prior appropriate cytogenomic testing (chromosomal microarray/CMA) to be nondiagnostic before WES in non‑time‑critical cases; only a karyotype is reported as nondiagnostic and no CMA is documented, so required prior testing is incomplete.",Not Specified,"BCBS_FEP coverage for WES is driven by the proband's phenotype and prior testing; while a sibling had a brief resolved unexplained event (BRUE), payer criteria do not specify this family history/consanguinity element as a discrete eligibility requirement for WES in this scenario.",Yes,"BCBS_FEP requires documentation of genetic counseling for WES; pre‑test genetic counseling has been completed and post‑test follow‑up is planned, meeting counseling requirements.",81415,The requested test is diagnostic whole exome sequencing; CPT code 81415 corresponds to exome sequence analysis and interpretation (proband/exome).,No,"Although the clinical indication and counseling/provider requirements are met, BCBS_FEP requires prior cytogenomic testing (CMA) to be nondiagnostic before authorizing WES in this non‑emergent neonatal case; CMA is not documented, so coverage criteria are not fully satisfied.",1990,2025,4015
Case10363,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) is being pursued.,Yes,"UHC WGS/WES coverage policies commonly include pediatric patients with congenital anomalies or unexplained birth defects; the patient is a 7‑year‑old child, which meets age expectations for pediatric genomic evaluation.",Not Specified,"The record states referral by a general practitioner and multiple genetic counseling visits, but does not explicitly identify the ordering provider specialty. UHC policies emphasize genetics expertise and counseling for complex genomic testing, but a specific ordering‑provider requirement is not documented in the supplied patient information.",Yes,"UHC criteria for WGS/WES include unexplained congenital anomalies or longstanding congenital findings after prior targeted testing; this patient has a congenital anomaly since birth and nondiagnostic prior targeted testing (FISH), meeting a clinical indication.",No,UHC typically requires prior appropriate targeted testing (often including chromosomal microarray [CMA] as first‑tier for congenital anomalies) before WGS; only FISH is documented as nondiagnostic and there is no documentation that CMA or other recommended prior tests were completed.,No,"UHC coverage criteria consider family history of a similarly affected relative or consanguinity relevant; the only family history documented is a maternal aunt with pancreatic cancer, which is not relevant to the child’s congenital anomaly per policy.",Yes,"UHC requires pre‑test genetic counseling for WGS/WES in many circumstances; the patient has been seen multiple times by a genetic counselor for pre‑test counseling and has plans for post‑test follow‑up, satisfying counseling requirements.",81425,"CPT 81425 corresponds to whole genome sequencing with interpretation/reporting, which best matches the requested WGS.",No,"Although age, clinical indication (congenital anomaly), and genetic counseling are met, UHC policy generally requires completion of appropriate prior testing (e.g., chromosomal microarray or other recommended first‑tier tests) before approving WGS. CMA or other required prior testing is not documented, so coverage would not be approved per payer criteria.",1999,2002,4001
Case9349,baseline,without_policy,iter2,WES,The patient record explicitly states referral for whole exome sequencing (WES).,Not Specified,"BCBS_FEP WES coverage criteria do not impose a strict age cutoff for exome testing; the patient is 5 years old which does not conflict with typical age guidance, and no payer-specific pediatric age restriction is specified in the information provided.",Not Specified,"BCBS_FEP policies commonly allow ordering by the treating clinician with appropriate documentation rather than restrict to a single specialty; the record shows a cardiologist referral and genetic counselor involvement, and no payer-specific ordering-provider restriction was provided.",No,"BCBS_FEP WES medical-necessity rules generally define covered indications (e.g., multiple congenital anomalies, global developmental delay/ID/autism, or complex multisystem unexplained phenotype). This patient has a single-organ congenital cardiac anomaly; that clinical presentation alone does not meet BCBS_FEP's defined WES indications.",No,For a single-organ cardiac phenotype BCBS_FEP policy expects targeted cardiac genetic testing (disease-specific gene panel) or other relevant focused tests prior to broad WES. Only nondiagnostic FISH was done; no prior targeted cardiomyopathy/arrhythmia gene panel or other recommended prior testing is documented.,Yes,"Family history is relevant: a paternal uncle with sudden unexplained death before age 35 raises concern for an inherited cardiac arrhythmia/cardiomyopathy, which BCBS_FEP recognizes as pertinent to genetic evaluation.",Yes,"BCBS_FEP requires documentation of pre-test genetic counseling for complex genomic tests; the record documents pre-test counseling by a genetic counselor and plans for post-test follow-up, satisfying counseling requirements.",81415,"CPT 81415 corresponds to clinical exome sequencing (proband-only), which matches the requested WES.",No,"Although counseling and relevant family history are documented, BCBS_FEP WES coverage criteria require an appropriate covered clinical indication (typically multisystem or neurodevelopmental phenotypes) or prior targeted testing when the presentation is single-organ. This patient has a single-organ congenital cardiac anomaly and has not completed recommended targeted cardiac gene testing; therefore WES does not meet BCBS_FEP medical-necessity/prior-test requirements and would not be covered.",1990,1978,3968
Case1428,baseline,without_policy,iter2,WGS,The patient information explicitly states whole genome sequencing (WGS) has been ordered.,Yes,UnitedHealthcare WES/WGS pediatric policy specifies age-based coverage for pediatric patients with suspected genetic disorders (typically pediatric cutoff ≤21 years); the patient is a 3‑week‑old infant and therefore meets age criteria.,Yes,"UHC policy requires ordering by or in consultation with an appropriate specialist (e.g., medical geneticist or genetic counselor); the test is being ordered by a medical geneticist, meeting provider requirements.",Yes,"UHC coverage criteria include infants with congenital anomalies or suspected single‑gene disorders or family history of neurodevelopmental disorders as indications for WES/WGS; this infant has Hirschsprung disease (a congenital condition) plus a sibling with severe intellectual disability, supporting a medical indication.",No,"UHC typically requires prior appropriate testing for unexplained DD/ID (commonly chromosomal microarray and Fragile X where applicable) before WES/WGS. Although Fragile X was done and nondiagnostic, there is no documentation of a chromosomal microarray (CMA), so required prior testing has not been completed.",Yes,"Family‑history criteria are relevant for WES/WGS and the patient has a first‑degree sibling with severe intellectual disability diagnosed by age 18, which is a pertinent family history.",No,"UHC policies require documented pre‑test genetic counseling by a qualified professional for WES/WGS. The case states there is no documented pre‑test genetic counseling, so counseling requirements are not met.",81425,"CPT code 81425 corresponds to whole genome sequencing (clinical WGS with interpretation), which matches the ordered test.",No,"Although age, provider, and clinical indication criteria are met, UnitedHealthcare requires prior testing (e.g., CMA) and documented pre‑test genetic counseling for WGS in this clinical context; those requirements are not satisfied here, so coverage would be denied.",1969,1980,3949
Case3359,baseline,without_policy,iter2,WES,The clinical note explicitly states 'Whole exome sequencing (WES) is being requested' for the 4-year-old with hypotonia and developmental concerns.,Yes,"UHC WES coverage policies specify pediatric patients with unexplained developmental delay/ID or neurodevelopmental disorders are eligible; the patient is 4 years old, which meets pediatric age-based eligibility.",Yes,"UHC generally requires an ordering clinician (physician/specialist) with documentation of medical necessity; the order is from a developmental pediatrician and pre-test counseling was done by a genetic counselor, which satisfies ordering/provider requirements.",Yes,UHC covers WES for unexplained developmental delay/intellectual disability or major neurodevelopmental concerns when prior testing nondiagnostic. The patient has significant hypotonia and ongoing developmental concerns consistent with those indications.,Yes,"UHC policies typically require prior chromosomal microarray as first‑line testing for developmental delay; the record states CMA was previously performed and was nondiagnostic, satisfying prior-test requirements.",Yes,"Family history criteria are relevant for genetic evaluation; the patient has a sibling with developmental delay, which is pertinent and supportive of genetic testing per UHC guidance.",Yes,"UHC requires documentation of genetic counseling for WES; the record documents pre-test counseling by a genetic counselor on multiple occasions and plans for post-test follow-up, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (proband or interpretation/reporting of exome sequencing), the appropriate code for the requested WES.",Yes,"Based on UHC coverage criteria: pediatric patient with unexplained developmental delay/hypotonia, nondiagnostic prior CMA, appropriate ordering provider involvement, documented genetic counseling, and relevant family history — all criteria for WES coverage are met.",1993,1369,3362
Case9978,baseline,without_policy,iter2,WES,The patient record explicitly states the patient is undergoing whole exome sequencing (WES) requested by the neurologist.,Not Specified,"UHC WES coverage criteria are driven by clinical presentation (e.g., unexplained early-onset epileptic encephalopathy/developmental disorder) rather than strict age cutoffs; no age exclusion is specified for this scenario.",Yes,"UHC policies require WES be ordered by an appropriate treating/qualified clinician (e.g., geneticist, neurologist); the ordering provider is a neurologist, which satisfies the ordering-provider requirement.",Yes,"UHC covers WES when there is a suspected genetic etiology such as early-onset epileptic encephalopathy/unexplained neurologic disorder beginning in infancy/early childhood; this patient had epilepsy onset before age 3 persisting into adulthood, meeting that clinical indication.",No,"UHC commonly requires prior appropriate testing (e.g., chromosomal microarray and/or targeted testing) before WES for developmental/neurologic indications; the record documents prior Fragile X testing only and does not document required prior CMA or other recommended prior tests.",Yes,"Family history is relevant to WES eligibility under UHC criteria; the patient has a brother with an inborn error of metabolism, which supports a heritable etiology.",Yes,"UHC requires pre-test genetic counseling for WES; the patient completed pre-test counseling with a genetic counselor and has post-test follow-up planned, meeting counseling requirements.",81415,"CPT 81415 corresponds to whole exome sequencing (interpretation and report), which matches the requested test.",No,"Although clinical indication, ordering provider, counseling, and family history support WES per UHC policy, required prior testing (e.g., chromosomal microarray/other recommended prior tests) is not documented; because a required prior test was not completed, coverage criteria are not fully met.",1973,1845,3818
Case22,baseline,without_policy,iter2,BRCA1/2,The case states the patient is 'undergoing BRCA1/2 testing' to evaluate hereditary predisposition for high-risk metastatic prostate cancer. This explicitly names BRCA1/2 testing.,Not Specified,BCBS FEP BRCA coverage is driven by personal/family cancer history and clinical indication rather than strict age cutoffs; no age-based exclusion for an 18-year-old with personal metastatic prostate cancer is specified in the policy.,Not Specified,BCBS FEP policies typically require an appropriate ordering clinician but do not mandate a specific specialty for BRCA testing; the record shows an ordering physician (neurologist) but the policy does not specify ordering-provider specialty requirements.,Yes,"BCBS FEP covers BRCA testing for individuals with a personal history of high-risk/metastatic prostate cancer and/or prostate cancer with intraductal/cribriform histology per NCCN-aligned criteria. The patient has metastatic high-risk prostate cancer with intraductal/cribriform histology, meeting a covered clinical indication.",Not Specified,BCBS FEP coverage for BRCA1/2 does not require completion of prior genetic tests (CMA is not a prerequisite); no specific prior-test requirement is stated in the policy and the nondiagnostic CMA does not affect BRCA eligibility.,Yes,Family history of a first-degree relative (father) with metastatic high-risk prostate cancer with intraductal/cribriform features is relevant to BCBS FEP BRCA coverage criteria and supports testing eligibility.,Yes,"BCBS FEP and standard coverage policies expect documented pre-test counseling for germline BRCA testing. The patient completed pre-test counseling and has post-test follow-up arranged, satisfying counseling requirements.",Not Specified,"The correct CPT codes for BRCA1 and BRCA2 sequence analysis (e.g., 81211, 81213) and associated deletion/duplication codes are not among the provided choices; therefore a precise mapping to the listed CPT options cannot be made.",Yes,"Applying BCBS FEP medical policy: the patient has a covered clinical indication (personal metastatic high-risk prostate cancer with intraductal/cribriform histology and a positive family history), documented pre-test counseling, and no disqualifying prior-test requirements—BRCA1/2 testing is therefore covered.",2011,1997,4008
Case5605,baseline,without_policy,iter2,WGS,The clinical note explicitly states the patient was referred for whole genome sequencing.,Yes,BCBS_FEP WES/WGS coverage is targeted to pediatric patients with congenital anomalies/early-onset suspected genetic disorders; the patient is 11 years old (pediatric) and therefore meets age-based eligibility.,Not Specified,"BCBS_FEP policies generally require appropriate clinical documentation and genetics involvement (eg, counseling) but do not rigidly require a specific ordering provider specialty in all cases; the record shows a referral by an obstetrician and counseling by a genetics specialist, but the explicit ordering-provider requirement is not specified in the provided information.",Yes,"BCBS_FEP supports WGS for unexplained major congenital anomalies after standard workup; the patient has a major congenital cardiac anomaly, which meets the medical indication for WGS.",Yes,"BCBS_FEP typically requires prior chromosomal microarray for congenital anomaly evaluation; the patient had a nondiagnostic CMA prior to WGS, satisfying prior testing requirements.",No,"Family-history–based eligibility would require relatives with similar congenital findings or consanguinity; the only family history documented is a maternal aunt with pancreatic cancer, which is not relevant to congenital cardiac anomaly eligibility.",Yes,BCBS_FEP requires documentation of pre-test genetic counseling for WES/WGS; the record states pre-test counseling was completed with a genetic specialist.,81425,"CPT 81425 corresponds to whole genome sequencing (clinical genome sequence analysis and interpretation), which matches the requested WGS.",Yes,"All applicable BCBS_FEP criteria are met: pediatric age, appropriate medical indication (major congenital cardiac anomaly), nondiagnostic prior CMA, and documented pre-test genetic counseling — therefore WGS is covered.",1969,2062,4031
Case19162,baseline,without_policy,iter2,WGS,The clinical note explicitly states the medical geneticist referred the neonate for whole genome sequencing (WGS) to evaluate an underlying genetic/metabolic cause.,Yes,BCBS_FEP policies that address genome/exome testing define pediatric/neonatal patients as eligible when presenting with suspected genetic disorders; the patient is a neonate and therefore meets age-based eligibility.,Yes,"BCBS_FEP typically requires a specialist/genetics provider order for WGS; the request was made by a medical geneticist, satisfying the ordering-provider requirement.",Yes,"Policy coverage criteria include infants with complex, unexplained neurologic abnormalities and suspected genetic/metabolic disease; this neonate has dystonia, ataxia, asymmetric weakness and a sibling with an IEM, meeting clinical indication.",No,"BCBS_FEP commonly requires prior first‑tier testing (e.g., chromosomal microarray) to be nondiagnostic before routine WGS except in critical-illness exceptions. The record documents nondiagnostic Fragile X but does not document prior CMA or other required prior testing, so required prior tests are not completed.",Yes,"There is a documented family history of an inborn error of metabolism in a sibling, which is relevant to eligibility under BCBS_FEP family-history criteria for genetic evaluation.",Yes,"BCBS_FEP requires pre‑test counseling for advanced genomic testing; pre-test counseling was completed with a genetic counselor and post-test follow-up is planned, meeting counseling requirements.",81425,"Among the provided CPT options, 81425 corresponds to whole genome sequencing analysis/interpretation and is the best match for WGS.",No,"Although age, ordering provider, clinical indication, family history, and counseling requirements are met, BCBS_FEP routine coverage generally requires prior first‑tier testing (e.g., chromosomal microarray) to be nondiagnostic before authorizing WGS. No documentation of prior CMA is provided, so coverage would not be approved under standard criteria (unless an exception for a critically ill infant is documented).",1999,2056,4055
Case15834,baseline,without_policy,iter2,WES,The clinical note explicitly states 'whole exome sequencing (WES) has been ordered.',Yes,"UHC WES criteria apply to pediatric patients with suspected genetic neurodevelopmental disorders; the patient is an infant with early signs of ASD, so age falls within the pediatric population covered by those criteria.",Yes,"UHC typically requires ordering/authorization by or in consultation with a genetics specialist or appropriate specialist; pre-test counseling was completed with a genetic specialist, indicating appropriate ordering/provider involvement.",No,"UHC medical necessity for WES generally requires unexplained developmental delay/intellectual disability, multiple congenital anomalies, or ASD with additional features (e.g., DD/ID, dysmorphic features). The record documents only early signs of ASD without documented DD/ID or congenital anomalies in the patient, so specific medical indication per policy is not met.",No,"UHC policies require prior first‑line testing (commonly chromosomal microarray and Fragile X testing) before WES. Fragile X testing was nondiagnostic, but no CMA is reported, so required prior testing has not been completed.",Yes,There is a family history of a maternal aunt with a congenital anomaly; UHC considers relevant family history when assessing genetic testing eligibility.,Yes,"UHC requires documented pre‑test genetic counseling for WES; the record states pre‑test counseling was completed with a genetic specialist, meeting that requirement.",81415,"CPT 81415 corresponds to clinical exome sequencing (WES), which matches the ordered test.",No,"Although age, provider, family history, and counseling requirements are met, UHC requires specific clinical indications (e.g., DD/ID or MCA) and completion of prior testing (notably chromosomal microarray) before WES; those criteria are not satisfied, therefore the test would not be covered per UHC policy.",1974,1962,3936
Case13,baseline,without_policy,iter2,WES,Clinical note explicitly states the patient was referred for whole exome sequencing (WES).,Not Specified,BCBS_FEP WES policy does not impose an age restriction for diagnostic WES; the patient is a newborn but age-based eligibility is not specified as a limiting criterion.,No,BCBS_FEP WES coverage typically requires ordering/authorization by a genetics professional or specialist with documented genetics expertise; the ordering provider is a general pediatrician and does not meet the specified provider requirement.,Yes,"BCBS_FEP criteria cover WES for individuals with multiple congenital anomalies not fitting a well-delineated syndrome and for unexplained neurodevelopmental/regressive disorders; the newborn has multiple congenital anomalies and a sibling with unexplained developmental regression, meeting medical indication.",No,"BCBS_FEP generally requires prior appropriate cytogenomic testing (chromosomal microarray) before WES; only a nondiagnostic karyotype was performed and CMA was not documented, so required prior testing is incomplete.",Yes,Family history of a sibling with unexplained developmental regression is relevant and meets family-history–based supportive criteria in BCBS_FEP WES policy.,Yes,"Pre-test genetic counseling was completed and post-test follow-up is planned, satisfying BCBS_FEP counseling requirements for WES.",81415,CPT 81415 corresponds to clinical whole exome sequencing (WES) interpretation/report for a proband and is the appropriate code for the requested test.,No,"Although medical indication, family history, and counseling requirements are met, BCBS_FEP requires prior cytogenomic testing (CMA) and appropriate ordering by a genetics professional; those requirements are not satisfied, so the test would not be covered as submitted.",1976,1743,3719
Case16487,baseline,without_policy,iter2,WES,The patient information explicitly states that whole exome sequencing (WES) was ordered.,Not Specified,UHC WES coverage criteria do not impose a strict age cutoff in typical policy language; the record documents a newborn but the payer policy does not specify an age-based exclusion or special age threshold for WES.,Not Specified,"UnitedHealthcare policy does not uniformly restrict ordering to a specific specialty (e.g., only geneticists) for WES in this clinical context; the documentation shows an oncologist ordered testing which is not explicitly disallowed by payer rules.",Yes,"UHC allows WES for patients with an unexplained, presumably genetic condition when prior targeted testing is nondiagnostic and a molecular diagnosis may affect management; this newborn has recurrent high‑risk BRUE (unexplained), nondiagnostic FISH, and a relevant family history, meeting medical indication criteria.",No,"UHC commonly requires prior appropriate cytogenetic testing such as chromosomal microarray (CMA) or other first‑tier tests before WES for non‑critically ill infants; only nondiagnostic FISH is documented and no CMA is reported, so required prior testing has not been completed.",Yes,"The family history includes a maternal aunt with a persistent severe immunologic/hematologic disorder, which is relevant and supportive per UHC criteria that consider family history in assessing need for WES.",Yes,"The record documents that pre‑test genetic counseling was completed with plans for post‑test genetic follow‑up, satisfying UHC requirements for counseling when specified for genomic testing.",81415,"81415 is the CPT code that corresponds to clinical exome sequencing (WES), which is the test requested.",No,"Although clinical indication, family history, and counseling are documented, coverage is not supported because required prior cytogenetic testing (e.g., CMA) is not documented and the case is not clearly a critically ill inpatient scenario that would permit bypassing prior test requirements under UHC policy.",1985,2114,4099
Case3677,baseline,without_policy,iter2,BRCA1/2,"The note states she is ""undergoing BRCA1/2 testing.""",Not Specified,UHC BRCA coverage is based on clinical/family indications rather than strict age cutoffs; no age-based exclusion is specified for BRCA1/2 testing in this clinical context.,Not Specified,UHC policies require an authorized/licensed ordering clinician and documentation of counseling but do not narrowly restrict ordering to a single specialty; the NP referral and completed counseling meet typical provider requirements.,Yes,"Per UHC/NCCN-based criteria, testing is indicated for individuals with a personal history of breast cancer and a strong family history of BRCA-related cancers (mother with pancreatic cancer and multiple additional affected maternal relatives).",Not Specified,UHC BRCA testing does not require prior genetic tests (CMA was done and nondiagnostic but is not a prerequisite). No specific prior test completion is required for BRCA1/2 testing.,Yes,"The patient has a relevant family history (mother with pancreatic cancer and at least two additional affected maternal relatives), which is a stated eligibility criterion for BRCA testing.",Yes,"UHC generally requires documentation of pre-test genetic counseling for BRCA testing; the patient completed pre-test counseling and plans post-test follow-up, satisfying counseling requirements.",81277,"Of the provided CPT choices, 81277 best corresponds to comprehensive BRCA1/BRCA2 gene testing (full gene analysis) used for BRCA1/2 diagnostic testing.",Yes,"The patient meets UHC clinical coverage criteria (personal breast cancer plus strong family history of BRCA-related cancers), has documented pre-test counseling, and ordering clinician is within typical authorized providers, so BRCA1/2 testing is covered.",1997,1809,3806
Case3474,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) is being ordered to assess an underlying genetic etiology.,Not Specified,UHC WGS/WES policies do not impose a strict age cut-off for testing in pediatric patients with congenital anomalies or neurodevelopmental concerns; the patient is a 5-year-old and age-based exclusion is not specified.,Yes,"UHC requires that testing be ordered/managed by an appropriate genetics provider; the order is from a medical geneticist, which satisfies provider requirements in the policy.",Yes,"UHC coverage criteria include patients with congenital structural anomalies and suspected syndromic/genetic disorder; the patient has congenital choanal atresia and a sibling with developmental delay, meeting medical indication for diagnostic WGS.",No,"UHC typically requires prior chromosomal microarray (CMA) or equivalent cytogenomic testing before WES/WGS unless clinically inappropriate; only a nondiagnostic karyotype is documented and no CMA was completed, so required prior testing is not satisfied.",Yes,"Family history criteria are relevant for WGS and the patient has a first-degree sibling with developmental delay, which is a relevant positive family history per the policy.",Yes,"UHC policies require documented pre-test genetic counseling for WES/WGS; the record states pre-test counseling was completed multiple times with planned post-test follow-up, satisfying counseling requirements.",81425,"CPT 81425 corresponds to whole genome sequencing (genomic sequence analysis—WGS), which matches the requested test.",No,"Although medical indication, provider type, counseling, and family history support WGS, UHC requires prior appropriate cytogenomic testing (typically chromosomal microarray) before authorizing WGS. CMA was not completed (only a nondiagnostic karyotype), therefore coverage criteria are not met and WGS would be denied pending required prior testing.",1982,1643,3625
Case15938,baseline,without_policy,iter2,WGS,The note explicitly states whole-genome sequencing (WGS) is being considered to identify a genetic cholestatic/metabolic etiology.,Not Specified,"UHC WES/WGS coverage criteria are based on clinical indication rather than strict age cutoffs; no explicit age-based exclusion applies to newborns in the policy, so age-specific eligibility is not specified.",Not Specified,UHC policies generally require an appropriate ordering clinician but do not rigidly restrict ordering to a single specialty in all cases; the provided information does not document a payer-mandated specialist requirement for WGS.,Yes,The infant has conjugated hyperbilirubinemia (neonatal cholestasis) with concern for a genetic cholestatic/metabolic etiology and a family history of a sibling with unexplained developmental regression—these meet UHC criteria for suspicion of an underlying genetic disorder warranting comprehensive genomic testing.,No,"UHC criteria typically expect prior appropriate diagnostic workup (e.g., targeted metabolic testing/gene panels or chromosomal microarray when indicated) before WGS; only a nondiagnostic karyotype is documented (karyotype is not equivalent to CMA), and no prior targeted metabolic or panel testing is documented.",Yes,"Family history is relevant per UHC criteria: there is an affected sibling with unexplained developmental regression, which supports genetic testing eligibility.",No,UHC typically requires documentation of pre-test genetic counseling/consent for WGS; the record states no pretest genetic counseling is documented.,81425,CPT 81425 corresponds to whole-genome sequencing (WGS) analysis and best matches the requested test.,No,"Although the clinical presentation and family history meet medical indications for comprehensive genomic testing, coverage requirements (documentation of required prior testing/workup and pre-test genetic counseling) are not met; therefore per UHC coverage criteria the request would not be approved as presented.",1987,1970,3957
Case4067,baseline,without_policy,iter2,WES,"The clinical note explicitly states ""whole exome sequencing (WES) has been ordered.""",Not Specified,UHC coverage for WES is generally driven by clinical indication rather than a specific strict age cutoff in published criteria; the patient is 5 years old but no payer-specific age restriction is provided in the record.,Not Specified,The documentation shows the order came from a developmental pediatrician; UHC policies commonly require an appropriate ordering clinician but the provided patient information does not state a specific payer requirement for ordering provider specialty.,Yes,"UHC medical-necessity criteria for WES commonly cover pediatric patients with unexplained neurodevelopmental disorders/complex neurologic phenotypes. This 5-year-old has significant hypotonia and was referred by a developmental pediatrician for evaluation of an underlying genetic etiology, which meets the clinical indication.",No,"UHC typically requires prior appropriate genomic testing such as chromosomal microarray (CMA) for unexplained developmental delay/ID before WES. The record reports only a nondiagnostic chromosomal karyotype (not CMA), so the required prior test has not been completed.",Yes,"The family history includes a paternal uncle with sudden unexplained death before age 35, which is relevant and noted in the record as raising concern for a heritable disorder.",No,UHC coverage expectations include documentation of pre-test genetic counseling/informed consent for WES. The provided information does not document that genetic counseling or consent occurred.,81415,"CPT 81415 corresponds to clinical exome (whole exome) sequencing for a proband, which matches the ordered WES.",No,"Although the patient meets the clinical indication (pediatric hypotonia referred by a developmental pediatrician and relevant family history), UHC requires prior appropriate testing (CMA rather than karyotype) and documentation of pre-test genetic counseling. Those prior requirements are not met in the record, so the test would not be covered as submitted.",1970,1728,3698
Case11514,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) has been requested to investigate a genetic cause of cholestatic liver disease.,Not Specified,UHC WES coverage criteria do not impose a strict age cutoff for exome testing; pediatric patients are generally eligible so no age-based exclusion applies to this 10-year-old.,Not Specified,"UHC policy does not restrict WES orders to a specific specialty (any qualified ordering clinician may request testing), so there is no specific specialty requirement that the oncologist fails to meet.",Yes,Patient has unexplained conjugated hyperbilirubinemia/cholestatic liver disease with a family history suggestive of an inborn error of metabolism and prior nondiagnostic testing; these facts meet UHC criteria for WES when a genetic etiology is suspected and prior testing is non-diagnostic.,Yes,"UHC often expects prior targeted testing when a single-gene diagnosis is strongly suspected, but for heterogeneous presentations like pediatric cholestasis WES is appropriate after nondiagnostic CMA; a CMA was performed and was nondiagnostic, satisfying prior-test expectations for this scenario.",Yes,"There is a documented family history of an inborn error of metabolism in a cousin, which is relevant to eligibility under UHC criteria that consider family history of genetic disease.",No,"UHC WES guidance requires documentation of pre-test genetic counseling or counseling by a qualified provider; the record states there is no documentation of pre-test genetic counseling, so this requirement is unmet.",81415,CPT 81415 corresponds to clinical whole exome sequencing (proband-only) and is the appropriate code for the requested WES.,No,"Although the clinical indication, prior nondiagnostic CMA, and family history support medical necessity under UHC WES criteria, lack of documented pre-test genetic counseling (a UHC requirement) prevents meeting all coverage conditions; therefore coverage is not approved.",2007,2228,4235
Case11981,baseline,without_policy,iter2,WGS,The record explicitly states Whole Genome Sequencing (WGS) is being requested to evaluate for an underlying genetic etiology.,Not Specified,UnitedHealthcare WGS/WES policies generally do not impose a strict single-age cutoff in pediatric neurodevelopmental indications; no age-based exclusion/inclusion criterion is specified in the provided information.,Not Specified,The record documents pre-test discussion with a genetic specialist but does not clearly state who is the ordering provider; UHC policies typically require appropriate ordering documentation but do not mandate a single specific ordering specialty in the provided data.,Yes,"Patient has persistent abnormal muscle tone from infancy with ongoing motor concerns and developmental surveillance—consistent with unexplained neurodevelopmental phenotype (an accepted indication under UHC WGS/WES criteria), and prior fragile X testing was nondiagnostic.",No,"UHC typically requires prior first‑tier testing (chromosomal microarray and/or other indicated targeted tests) for unexplained developmental delay/ID before WES/WGS; the record documents fragile X testing but does not document prior CMA, so required prior testing is not shown as completed.",Yes,Family history of a maternal uncle with a severe immunologic disorder is reported; family history is included in UHC considerations and is potentially relevant to genetic evaluation.,Yes,"Pre-test discussion with a genetic specialist is documented, satisfying UHC requirements for genetic counseling prior to WES/WGS.",81425,"CPT 81425 corresponds to whole genome sequencing with analysis and report, which matches the requested WGS.",No,"Although the clinical indication and genetic counseling meet UHC criteria, required prior testing (notably CMA/first‑tier chromosomal microarray) was not documented as completed; failing prior-test requirements leads to noncoverage per UHC policy.",1992,2070,4062
Case7682,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested.,Not Specified,UHC WES coverage is driven by clinical indications (developmental delay/multiple congenital anomalies) rather than a strict age cutoff; no age-based exclusion applies to this 9‑year‑old in the policy.,Yes,"UHC typically requires ordering by or in consultation with a genetics specialist; the record documents pre‑test counseling by a genetic specialist with plans for post‑test follow‑up, satisfying ordering/consultation requirements.",Yes,"UHC considers WES medically necessary for unexplained multiple congenital anomalies affecting multiple organ systems and developmental delay/intellectual disability; this 9‑year‑old has multiple congenital abnormalities and developmental concerns, meeting those clinical indications.",No,UHC generally requires prior chromosomal microarray (CMA) or equivalent high‑resolution cytogenomic testing before WES; the record documents a nondiagnostic karyotype but does not document a prior CMA.,Yes,"The patient has a family history of developmental delay in a sibling, which is relevant to eligibility under UHC WES criteria (family history supports genetic evaluation).",Yes,UHC requires pre‑test genetic counseling and a plan for post‑test follow‑up; the record documents pre‑test counseling by a genetic specialist and plans for post‑test follow‑up.,81415,CPT 81415 corresponds to clinical whole exome sequencing and is the appropriate code for WES.,No,"Although clinical indications, genetic counseling, ordering/consultation and family history meet UHC criteria for WES, the required prior cytogenomic testing (CMA) is not documented (only a nondiagnostic karyotype), so per UHC coverage rules the WES request is not covered at this time.",1973,1889,3862
Case3494,baseline,without_policy,iter2,WES,The chart states whole exome sequencing (WES) is being requested for diagnostic clarification.,Not Specified,"Cigna WES medical policy does not impose a specific age cutoff for coverage; pediatric patients (including neonates/infants) may be eligible, so no age-based exclusion applies.",Yes,"Cigna requires tests be ordered by a qualified clinician; the request was placed by the infant’s general pediatrician (a licensed ordering physician), which satisfies ordering-provider requirements in the policy.",Yes,Cigna criteria consider WES medically appropriate for individuals with congenital anomalies and/or an evolving complex neurodevelopmental disorder suggestive of a genetic etiology; this 6‑week‑old has a congenital abnormality and concern for evolving neurodevelopmental disorder.,No,"Cigna policy generally requires first‑line testing (e.g., chromosomal microarray) for multiple congenital anomalies/developmental delay prior to WES unless there is a documented reason to proceed directly; the patient has had no prior genetic testing and no justification for bypassing CMA is documented.",Yes,"There is a positive family history (a sibling with dysmorphic features), which is relevant and supports genetic evaluation per Cigna criteria.",No,"Cigna requires documentation of pre‑test (and often post‑test) genetic counseling by a qualified provider; the family declined genetic counseling, so counseling requirements are not met.",81415,CPT 81415 corresponds to clinical exome sequencing (WES) and is the appropriate CPT code for the requested test.,No,"Although the clinical indication and ordering provider are consistent with Cigna coverage criteria, required prerequisites (documentation of prior first‑line testing such as CMA or a justified reason to omit it, and documented genetic counseling) are not met; therefore under Cigna policy the WES request is not covered as submitted.",1975,1958,3933
Case7014,baseline,without_policy,iter2,WGS,Patient record explicitly states whole genome sequencing (WGS) is being requested.,Yes,"UHC genomic sequencing policy includes pediatric patients with congenital anomalies; the patient is a 7‑week infant, which meets age‑based pediatric eligibility.",Yes,"Policy requires ordering/oversight by an appropriate specialist and/or genetics provider; the referral is from neurology and pre‑test counseling was completed with a genetic specialist, so provider requirements are met.",Yes,"UHC criteria cover WGS for unexplained multiple congenital anomalies or an atypical presentation not fitting a well‑delineated syndrome; the infant has multiple congenital anomalies and a nondiagnostic prior karyotype, meeting clinical indication.",No,UHC generally requires prior standard cytogenomic testing (chromosomal microarray) as first‑tier for multiple congenital anomalies; only a nondiagnostic karyotype is documented and CMA is not documented as completed.,Yes,"Policy lists family history of related congenital anomalies as supportive information for sequencing; the record documents a maternal aunt with a congenital anomaly, which is relevant family history.",Yes,UHC requires documented pre‑test genetic counseling by a qualified genetics professional for genomic sequencing; pre‑test counseling was completed with a genetic specialist and results will be reviewed with family and neurology.,81425,81425 corresponds to whole genome sequencing and is the CPT most consistent with the requested WGS in the options provided.,No,"Although age, provider, clinical indication, counseling, and family history meet UHC criteria, required prior testing (chromosomal microarray/CMA) is not documented; per UHC coverage rules WGS would not be approved until required prior testing is completed or documented as unnecessary.",1983,2119,4102
Case13517,baseline,without_policy,iter2,WES,The patient record explicitly states 'whole exome sequencing (WES) was ordered' to evaluate an underlying genetic cause.,Not Specified,"UHC WES coverage criteria do not impose a strict age cutoff in typical policy language; the patient is 16 (pediatric), but the policy does not specify an age-based exclusion or specific age requirement.",Not Specified,"UHC policies usually require appropriate ordering/documentation and genetic counseling but do not universally restrict ordering to a single specialty; the record shows referral by a developmental pediatrician and counseling by a genetic counselor, but the policy does not strictly specify an ordering-provider specialty in this scenario.",Yes,"UHC considers WES medically necessary for suspected monogenic disorders or unexplained inherited conditions when targeted testing is nondiagnostic or not available; the patient has conjugated hyperbilirubinemia with a sibling having lab abnormalities suggestive of an inborn error of metabolism, meeting a documented clinical indication for WES.",Not Specified,"UHC WES criteria vary by clinical context (e.g., neurodevelopmental vs metabolic); specific mandatory prior tests (e.g., CMA, metabolic biochemical testing, targeted panels) are not universally required for all indications here and the record does not state completion of any required prior metabolic gene panels or biochemical testing, so prior-test requirements are not clearly specified or documented.",Yes,"Family history criteria are relevant for WES coverage; the patient has a sibling with laboratory abnormalities suggestive of an inborn error of metabolism, which supports testing per payer criteria.",Yes,"UHC typically requires documentation of pre-test genetic counseling for WES; the record states pre-test counseling was completed with a genetic counselor and post-test counseling is planned, satisfying counseling requirements.",81415,"The ordered test is whole exome sequencing (proband), which corresponds to CPT code 81415 for exome sequencing (proband-only) under typical coding conventions.",Yes,"Applying UHC coverage criteria: the patient has a clinically appropriate indication (suspected inborn error of metabolism with an affected sibling), pre-test genetic counseling is documented, and WES is an appropriate next-step diagnostic test in this context, so the test meets medical necessity and is covered.",1991,1966,3957
Case14127,baseline,without_policy,iter2,WES,The note explicitly states 'whole exome sequencing (WES) is being pursued' for evaluation of the patient.,Not Specified,"UHC WES coverage criteria are driven by clinical indication rather than a strict age cutoff; no payer-specific age exclusion is stated for this scenario, so age-based eligibility is not specified.",Yes,"UHC policies require ordering/coordination by a genetics provider or documentation of genetics involvement; the medical geneticist is coordinating testing and a genetics counselor was involved, meeting ordering provider requirements.",Yes,"UHC covers WES for unexplained global developmental delay/ intellectual disability when workup is unrevealing; the patient has lifelong GDD with cognitive/adaptive deficits, which meets the clinical indication.",No,"UHC typically requires prior first‑tier testing such as chromosomal microarray (CMA) (and depending on sex, Fragile X testing) before WES for GDD/ID. Only nondiagnostic FISH was done (not equivalent to CMA), so required prior testing has not been completed.",Yes,"Payer criteria recognize a family history of similar early‑onset neurodevelopmental disorders as supportive for WES; there is a sibling with epileptic encephalopathy onset before age 3, which is relevant.",Yes,"UHC requires documentation of pre‑test counseling/consent for WES; the patient saw a genetic counselor for pre‑test counseling and will return for post‑test counseling, satisfying counseling requirements.",81415,CPT 81415 corresponds to whole exome sequencing (sequence analysis of the exome) and best matches the requested WES.,No,"Although clinical indication, genetics provider involvement, family history, and counseling requirements are met, UHC requires prior first‑tier testing (e.g., CMA) before approving WES for GDD/ID; CMA was not completed (only nondiagnostic FISH), so coverage is not supported at this time.",2003,1658,3661
Case15820,baseline,without_policy,iter2,CMA,The clinical note explicitly states chromosomal microarray (CMA) has been ordered to evaluate for copy number variants in a patient with developmental delay/intellectual disability.,Not Specified,Cigna CMA coverage criteria are based on clinical indication (unexplained developmental delay/intellectual disability) and do not impose an age limit for testing in this clinical context; the policy does not specify age-based exclusion.,Not Specified,Cigna's CMA policy does not mandate a specific ordering provider specialty for coverage; no provider-type restriction is documented in the patient information.,Yes,"Cigna covers CMA for individuals with unexplained developmental delay/intellectual disability; the patient is a 31-year-old with developmental delay and intellectual disability without a suspected specific syndrome, meeting the clinical indication.",Not Specified,Cigna's policy generally allows CMA as a first‑line test for unexplained developmental delay/ID and does not require completion of other genetic tests prior to CMA; no required prior tests are documented.,Not Specified,CMA eligibility criteria do not hinge on family history or consanguinity; the noted family history (mother with early-onset breast cancer) is relevant to BRCA testing but not to CMA coverage criteria.,Not Specified,"While genetic counseling is good clinical practice and the patient completed pre-test counseling, Cigna's CMA coverage criteria do not explicitly require documented genetic counseling as a coverage precondition in this scenario.",81425,"CPT code 81425 corresponds to chromosomal microarray analysis for copy number variant detection (CMA), matching the ordered test.",Yes,"Per Cigna policy, CMA is covered for unexplained developmental delay/intellectual disability; the patient meets the medical indication, no disqualifying age/provider/prior-test requirements apply, and counseling has been completed.",1984,1754,3738
Case13675,baseline,without_policy,iter2,WGS,The case statement explicitly says whole genome sequencing (WGS) is being pursued for diagnostic clarification.,Yes,"UHC genomic sequencing criteria specify pediatric/infant coverage for suspected genetic disorders or congenital anomalies; the patient is an 8‑week‑old infant, which meets age-based eligibility.",Yes,UHC allows ordering by the treating physician/specialist managing the neonate; the order is from a neonatologist (an appropriate treating specialist).,Yes,UHC coverage criteria for genomic sequencing include infants with congenital sensory impairment/multiple congenital anomalies or suspected monogenic disorder; this infant has significant congenital hearing and/or visual impairment and prior testing was nondiagnostic.,No,UHC generally requires prior chromosomal microarray (or equivalent cytogenetic testing) before WGS for congenital anomalies/developmental concerns; only FISH (nondiagnostic) was performed and no CMA is documented.,Not Specified,"Although a family history of paternal long QT is documented (clinically relevant for interpretation), UHC WGS eligibility is not dependent on presence/absence of family history, so family history is not a specified gating criterion.",No,UHC genomic sequencing policies require documentation of pre‑test genetic counseling/informed consent by a qualified professional; no pre‑test genetic counseling is documented for this request.,81425,"CPT 81425 corresponds to whole genome sequencing (WGS) analysis and interpretation (proband only), matching the requested test.",No,"Despite appropriate age, provider, and medical indication, required prior testing (CMA) and documented pre‑test genetic counseling are not present per UHC policy, so coverage criteria are not fully met.",1994,2243,4237
Case2162,baseline,without_policy,iter2,WGS,The patient information explicitly states the infant was referred for whole genome sequencing.,Not Specified,BCBS_FEP WES/WGS coverage criteria do not impose a strict age cutoff for sequencing; the policy is indication-based rather than limited by infant age.,Not Specified,The provided patient information does not indicate a payer-imposed restriction by specific ordering provider specialty; BCBS_FEP policies typically require an appropriate ordering clinician but do not always mandate a specific specialty in the chart provided.,Yes,BCBS_FEP considers WGS medically indicated for unexplained multiple congenital anomalies affecting multiple organ systems; the infant meets this clinical indication.,No,"BCBS_FEP criteria for WES/WGS generally expect prior appropriate testing (e.g., chromosomal microarray and targeted testing such as Fragile X where applicable). Fragile X was nondiagnostic but there is no documentation of chromosomal microarray having been completed.",Not Specified,"While the family history (an older sibling with autism) is noted and may be supportive, BCBS_FEP WGS coverage criteria are driven by the proband's phenotype; the payer policy does not make family history/consanguinity a required qualifying criterion in this context.",Yes,"BCBS_FEP typically expects documentation of pre-test genetic counseling for clinical WGS; the record states pre-test counseling was completed with plans for post-test follow-up, meeting that requirement.",81425,"Among the offered CPT choices, 81425 corresponds to clinical whole genome sequencing (WGS) interpretation and report.",No,"Although the infant meets the clinical indication and genetic counseling requirement, BCBS_FEP generally requires completion/documentation of prior appropriate testing (notably chromosomal microarray) before approving WGS for non–critically ill infants; because CMA is not documented as completed, the request would not meet the payer's prior test requirement and would be denied.",1965,2670,4635
Case7376,baseline,without_policy,iter2,WES,The note explicitly states whole exome sequencing (WES) has been ordered for diagnostic clarification.,Not Specified,UHC sequencing policies do not impose strict upper/lower age limits for WES; age-based eligibility is not specified for WES and the 73-year age does not conflict with policy.,Yes,"UHC requires testing be ordered by or in consultation with appropriate clinicians/genetics professionals; the patient was referred by a neurologist and pre-test counseling was completed with a genetic specialist, satisfying ordering/provider requirements.",Yes,UHC considers WES medically necessary for unexplained major abnormalities or suspected genetic disorders after prior testing; the patient has an unexplained major abnormality involving ≥1 organ system and a suspected genetic etiology.,Yes,"UHC requires prior appropriate genetic testing where indicated; the patient had prior FISH testing that was nondiagnostic, and appropriate prior testing has been documented before WES.",Yes,The patient reports a sister with triple-negative breast cancer; this positive family history is relevant to consideration of hereditary predisposition and supports genetic evaluation.,Yes,"UHC requires pre‑test genetic counseling for sequence-based testing; the patient completed pre-test counseling with a genetic specialist, meeting counseling requirements.",81415,"CPT 81415 is the correct code for whole exome sequencing (proband or singleton exome), which corresponds to the ordered WES.",Yes,"Patient meets UHC coverage criteria: unexplained major abnormality suggesting genetic etiology, prior targeted testing nondiagnostic, pre-test genetic counseling documented, and appropriate provider involvement; therefore WES is covered.",1983,1971,3954
Case11124,baseline,without_policy,iter2,WES,The clinical note explicitly states whole-exome sequencing (WES) has been ordered.,Not Specified,UHC WES coverage policies are indication-based (developmental delay/possible genetic disorder) and do not impose a specific age cutoff in this clinical context; the record only states 'infant' but payer age-specific restrictions are not specified.,Not Specified,UHC medical policy does not mandate a specific ordering provider specialty for WES in this setting (any qualified ordering physician/genetics team may order); the note indicates referral by an oncologist but the policy does not explicitly restrict ordering to a subspecialist.,Yes,"UHC coverage criteria for WES include unexplained developmental delay or suspected genetic disorder. The infant has developmental delay and a suspicious family history, satisfying a covered medical indication per payer criteria.",No,"UHC typically requires prior chromosome microarray (CMA) or equivalent cytogenetic testing before WES for developmental delay. The record documents prior FISH was nondiagnostic but does not document a CMA, so required prior testing has not been completed.",Yes,"The family history notes an older sibling with significant childhood-onset hearing impairment, which is relevant and supports hereditary etiology per payer criteria for comprehensive exomic testing.",Yes,"UHC requires documentation of pre-test genetic counseling for WES. The record states pre-test counseling was completed and post-test counseling is planned, meeting counseling requirements.",81415,CPT code 81415 corresponds to exome sequencing (WES) and best fits the ordered test.,No,"Although the patient meets clinical indications and genetic counseling is documented, UHC requires completion of specified prior testing (e.g., CMA) before approving WES. Only nondiagnostic FISH is documented and no CMA is recorded, so coverage would be denied pending completion/documentation of required prior testing.",1978,1446,3424
Case8051,baseline,without_policy,iter2,WES,The record explicitly states 'whole exome sequencing (WES) ordered.',Not Specified,"BCBS_FEP WES coverage criteria are driven by clinical indications (congenital anomalies, developmental disorders) rather than a strict age cutoff; the infant's age (5 weeks) is not precluded but no payer-specific age limit is stated in the information provided.",Not Specified,The provided patient/payer information does not state any BCBS_FEP requirement that WES must be ordered by a specific specialty; ordering clinician is family medicine but no explicit ordering-provider restriction is provided.,Yes,"Clinical criteria for WES typically include unexplained major congenital anomalies or suspected syndromic etiology; this infant has a major congenital cardiac anomaly with concern for syndromic association (maternal short stature) and prior targeted testing nondiagnostic, meeting those indications.",No,"Many BCBS_FEP WES policies require prior appropriate cytogenomic testing (eg, chromosomal microarray) for congenital anomalies; the record documents prior FISH was nondiagnostic but does not document a CMA, so required prior testing appears incomplete.",Yes,"Family history noted: mother with short stature raising concern for a growth-related genetic condition, which is relevant to eligibility and interpretation of WES.",Yes,"Pre-test genetic counseling was completed and follow-up is planned after results, satisfying typical BCBS_FEP counseling requirement for complex genomic testing.",81415,The test requested is whole exome sequencing; CPT 81415 is the code that corresponds to exome sequencing in the provided answer set.,No,"Although clinical indication, family history, and pre-test counseling are met, coverage is not supported because required prior cytogenomic testing (eg, chromosomal microarray) is not documented; therefore BCBS_FEP coverage criteria are not fully satisfied.",1987,1827,3814
Case19905,baseline,without_policy,iter2,WES,The case explicitly states the patient is being considered for whole exome sequencing (WES).,Not Specified,UHC genomic sequencing policies do not impose a strict age cutoff for WES; pediatric status supports testing but age-based eligibility is not specifically defined in policy.,Yes,"UHC generally requires an appropriate ordering clinician (e.g., genetics specialist or treating specialist) and the order is from a developmental pediatrician, an appropriate specialist per payer practice.",Yes,"UHC covers WES for patients with unexplained multiple congenital anomalies/developmental concerns after prior diagnostic testing is non‑diagnostic; this 3‑year‑old has multiple congenital anomalies and developmental referral, meeting the clinical indication.",No,"UHC typically requires prior standard testing (eg, chromosomal microarray and/or other recommended targeted tests) before WES; only a nondiagnostic karyotype is documented and CMA was not completed, so required prior testing is not satisfied.",No,"Coverage family history criteria relate to similar or concordant familial conditions relevant to the tested phenotype. The noted maternal long QT syndrome is not described as related to the patient's congenital anomalies, so no relevant family history is present per policy criteria.",No,UHC policies require documentation of pre‑test genetic counseling or counseling by an appropriate provider for genomic sequencing; the record states no genetic counseling has been conducted.,81415,CPT 81415 corresponds to clinical exome sequencing (proband only) and is the appropriate code for WES as requested.,No,"Although the patient meets the clinical indication for WES, payer (UHC) coverage requires completion of prerequisite testing (eg, CMA) and documentation of genetic counseling before WES is approved; those requirements have not been met, so the test is not covered as currently documented.",1955,1564,3519
Case10850,baseline,without_policy,iter2,WGS,The patient information explicitly states whole genome sequencing (WGS) has been ordered.,Yes,"UnitedHealthcare pediatric genomic testing criteria cover sequencing for children/adolescents with unexplained global developmental delay/intellectual disability; the patient is 13 years old, which meets pediatric age-based eligibility.",Not Specified,"UHC medical necessity policies commonly require an appropriate ordering clinician and documentation but do not universally mandate a specific specialty (e.g., must be a geneticist). The record shows a developmental pediatrician ordered the test, but the payer policy does not explicitly restrict ordering to a particular specialty in this scenario.",Yes,"UHC criteria consider genomic sequencing medically necessary for pediatric patients with unexplained global developmental delay/ID after appropriate first‑tier testing; the patient has global developmental delay, which meets the clinical indication for sequencing.",No,"UHC typically requires prior first‑tier testing (chromosomal microarray and other appropriate targeted tests) before approving WES/WGS. The record notes prior FISH was nondiagnostic but does not document chromosomal microarray (CMA) or other required prior testing, so required prior testing is incomplete.",Yes,"The patient has a family history of an aunt with dysmorphic features; while not a first‑degree relative, this is relevant family history that supports a genetic etiology per payer criteria for consideration.",Yes,"UHC requires documentation of genetic counseling for genomic sequencing; the family completed pre‑test genetic counseling with plans for post‑test follow‑up, meeting counseling requirements.",81425,"CPT 81425 corresponds to whole genome sequencing (genomic sequencing procedure, whole genome), which matches the ordered WGS.",No,"Although age, clinical indication (global developmental delay), documented pre‑test genetic counseling, and supporting family history meet UHC criteria, coverage is not supported because required prior testing (notably chromosomal microarray) is not documented. Per UHC policy, WGS would typically be denied/held until first‑tier testing requirements are completed.",1975,1863,3838
Case19321,baseline,without_policy,iter2,WES,The note explicitly states whole exome sequencing (WES) is being pursued to investigate a possible genetic etiology for the patient's neurodevelopmental disorder.,Yes,UHC coverage criteria specify WES for pediatric patients with unexplained neurodevelopmental disorders (developmental delay/autism); the patient is 1 year old and meets pediatric age-based criteria.,Yes,"UHC typically requires ordering by an appropriate treating clinician (e.g., neurologist, geneticist, pediatrician); the test was ordered/referral by a neurologist, which meets provider requirements.",Yes,UHC medical necessity criteria include unexplained complex neurodevelopmental disorder and features concerning for autism spectrum disorder; the patient has these indications and prior CMA was nondiagnostic.,Yes,"UHC generally requires prior chromosomal microarray as first‑line testing for developmental disorders; the record states CMA testing was nondiagnostic, satisfying the prior-test requirement.",Yes,"A relevant family history is present (maternal aunt with multiple congenital anomalies), which supports genetic evaluation per policy family-history considerations.",Yes,UHC requires pre‑test (and post‑test) genetic counseling for WES; the record documents pre‑test genetic counseling and plans for post‑test follow‑up.,81415,"CPT 81415 corresponds to clinical exome sequencing (WES) including interpretation, which matches the requested test.",Yes,"All applicable UHC coverage criteria are met: pediatric age, appropriate medical indication (complex neurodevelopmental disorder with ASD features), required prior CMA completed and nondiagnostic, ordering clinician is appropriate neurologist, and pre‑test genetic counseling documented.",1982,1785,3767
Case2496,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested.,Not Specified,UHC WES criteria are typically driven by clinical indication rather than strict patient age limits; the record describes a 32‑week fetus but no payer age restriction is specified in the clinical information.,Not Specified,The documentation lists the ordering provider as a neonatologist but the provided information and UHC criteria summary do not specify a required ordering provider specialty in this case.,Yes,"UHC covers WES when there is a suspected genetic disorder such as fetal structural/clinical abnormalities, especially with parental consanguinity and family history suggestive of autosomal recessive disease; the record documents consanguinity, concern for AR conditions, fetal imaging concerns and a sibling with unexplained early death—meeting medical indication criteria.",No,"UHC prenatal WES coverage commonly requires prior standard genomic testing (e.g., chromosome analysis/CMA) or targeted testing to be nondiagnostic; only prior FISH is documented as nondiagnostic and chromosomal microarray/karyotype are not reported as completed.",Yes,"The patient has parental consanguinity and a family history of sudden unexplained death in a sibling <35, both relevant and recognized criteria supporting WES eligibility.",No,UHC typically requires documented pre‑test genetic counseling for WES/WGS; the record explicitly states no genetic counseling has been completed.,81415,"CPT 81415 corresponds to clinical whole exome sequencing (WES), which is the test requested.",No,"Although clinical indications (fetal anomalies, consanguinity, family history) support WES, required prior testing (e.g., CMA/karyotype) and documented genetic counseling are not completed as required by UHC coverage policies, so coverage would likely be denied until those prerequisites are met.",1995,1765,3760
Case6867,baseline,without_policy,iter2,BRCA1/2,The patient presentation explicitly states she presents for BRCA1 and BRCA2 testing.,Not Answerable,"BCBS FEP BRCA criteria include age-based thresholds tied to age at cancer diagnosis (e.g., breast cancer diagnosed ≤50). The record gives the patient's current age (50) but does not state her age at breast cancer diagnosis, so age-based eligibility cannot be determined from the provided information.",Not Specified,"The provided patient information does not indicate a BCBS_FEP requirement for a specific ordering provider specialty; nurse practitioners commonly may order genetic testing and the case notes an NP referral plus genetics counselor involvement, but the policy does not specify a restricting provider type in the materials given.",Yes,"BCBS_FEP BRCA coverage includes individuals with a first‑degree relative with prostate cancer with aggressive/intraductal features and/or a first‑degree relative with breast cancer at or before age 50. The patient has a brother with metastatic prostate cancer with intraductal features and a mother with breast cancer at age 50, so she meets medical indication criteria.",Not Specified,BCBS_FEP germline BRCA testing typically does not require completion of other prior genetic tests as a prerequisite; no specific prior-test requirement is documented in the provided information.,Yes,"The patient has relevant family history: a brother with metastatic prostate cancer with intraductal features (first‑degree relative) and a mother with breast cancer at age 50, which are relevant to BRCA test eligibility.",Yes,"BCBS_FEP generally expects documentation of pre‑test genetic counseling; the record documents multiple pre‑test counseling visits with a genetic counselor, satisfying counseling requirements.",Not Specified,"The appropriate CPT codes for full BRCA1/BRCA2 sequencing are 81211/81213 (and related deletion/duplication codes), which are not among the provided options (81162, 81277, 81228, 81415, 81425). Therefore none of the listed choices precisely match standard BRCA1/2 full testing.",Yes,"Applying BCBS_FEP BRCA coverage criteria to the facts: the patient has qualifying family history (brother with intraductal metastatic prostate cancer; mother with breast cancer at age 50) and has documented pre‑test genetic counseling. Although age at the patient's breast cancer diagnosis is not provided, the available family and personal history meet BCBS_FEP indications for BRCA testing, so the test is covered.",1986,2989,4975
Case1130,baseline,without_policy,iter2,WES,The clinical note explicitly states the patient is undergoing whole exome sequencing (WES) to assess for an underlying genetic etiology.,Not Specified,UHC WES coverage criteria are typically driven by clinical indication rather than strict age cutoffs; no specific age-based exclusion or requirement is stated for WES in the provided information.,Not Specified,"The provided information does not state any payer-imposed ordering-provider specialty requirement; although the patient was referred by cardiology and has genetic counselor involvement, no explicit ordering-provider restriction is documented.",Yes,"UHC covers WES when there is an unexplained suspected genetic condition such as persistent seizures with evaluation for an underlying genetic etiology; the patient has persistent seizures and is being evaluated for a genetic cause, meeting that clinical indication.",No,"UHC WES policies commonly require prior appropriate targeted testing (e.g., disease-specific gene panel or other recommended molecular testing) to be non-diagnostic before WES; the record only documents nondiagnostic FISH and does not document prior targeted gene panel or other recommended prior molecular testing.",No,Family history noted (sister with ovarian/fallopian tube/peritoneal carcinoma) is not a family history of a similar neurologic phenotype or consanguinity relevant to WES eligibility per typical payer criteria; no relevant family history for seizure disorder is documented.,Yes,"UHC commonly requires documentation of pre-test genetic counseling for germline genomic testing; the patient has seen a genetic counselor multiple times with plans for post-test follow-up, satisfying counseling requirements.",81415,"CPT 81415 corresponds to exome sequencing (proband only), which best matches the requested WES for this patient.",No,"Although the patient meets a medical indication for WES and has documented genetic counseling, typical UHC coverage requires prior appropriate targeted molecular testing (e.g., disease-specific gene panel or other recommended testing) to be non-diagnostic; only nondiagnostic FISH is documented and no prior gene panel/CMA is noted, so coverage criteria are not fully met.",1989,1742,3731
Case5303,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states the patient was referred for BRCA1 and BRCA2 testing.,Not Specified,"UHC BRCA policies do not impose a single universal age cutoff for ordering BRCA testing; instead they reference ages of diagnosis in the proband or relatives for medical-necessity criteria (e.g., early-onset breast cancer ≤45). The patient is 37, but age alone is not a standalone eligibility rule in the policy.",Not Specified,UHC policies typically require an ordering licensed clinician and documentation (including counseling) but do not restrict ordering to a specific specialty in all instances. The record only lists neurology as the referring service; no payer-specific specialty exclusion is documented here.,No,"UHC BRCA medical-necessity criteria require a personal history of relevant cancers or a family history meeting defined thresholds (e.g., first- or second-degree relatives with breast/ovarian/pancreatic/prostate cancer at specified ages). This patient has a neurologic abnormality and a brother who died suddenly (no history of breast/ovarian cancer), so she does not meet the defined BRCA testing indications.",No,"For unaffected individuals, UHC policy generally prefers/testing requires evaluation of affected family members first or documentation that affected relative testing is unavailable. The patient has had no prior genetic testing of affected relatives, so required prior-family-member testing/documentation is not completed.",No,"The family history provided (brother died suddenly <35) does not include breast, ovarian, pancreatic, or related cancers specified in UHC BRCA family-history eligibility criteria; therefore relevant family-history criteria are not met.",No,"UHC BRCA policies require documentation of pre-test genetic counseling or equivalent informed consent in many instances. The record states no pre-test genetic counseling was performed, so counseling requirements are not met.",81228,"Among the provided CPT options, 81228 is the only single-gene style (812xx series) code listed and is the best available choice to represent targeted BRCA1/2 single-gene testing compared with panel/exome/genome codes (81415/81425).",No,"Per UHC BRCA coverage criteria: patient lacks qualifying personal or relevant family cancer history, has not completed recommended prior-family-member testing, and no pre-test genetic counseling was documented. Based on these payer-specific requirements, BRCA testing is not covered for this patient.",1960,2396,4356
Case7447,baseline,without_policy,iter2,WGS,Clinical note explicitly states the cardiologist ordered whole genome sequencing (WGS) on the fetus at 33 weeks.,Yes,BCBS_FEP WGS policy allows testing in the prenatal setting for a fetus with a major structural anomaly; gestational age 33 weeks meets the payer's age/setting applicability (no exclusion for prenatal age).,Yes,"BCBS_FEP permits ordering by an appropriate specialist managing the condition (e.g., fetal cardiologist/MFM or other treating specialist); the cardiologist is an appropriate ordering provider per policy.",Yes,Policy medical indications include a fetus with a severe/isolated structural congenital anomaly where a genetic etiology is suspected; isolated severe congenital heart defect at 33 weeks meets that indication.,No,"BCBS_FEP generally requires prior standard genetic testing (e.g., chromosomal microarray and/or karyotype) to be completed and nondiagnostic before WGS; there is no documentation that CMA or standard prenatal cytogenetic testing was completed.",No,"Although there is a maternal aunt with triple‑negative breast cancer, that family history is unrelated to the fetal structural heart defect and does not satisfy any family‑history/consanguinity criteria relevant to WGS eligibility under the payer policy.",No,BCBS_FEP requires documentation of pre‑test genetic counseling for high‑complexity genomic tests like WGS; the record states there is no documentation of pre‑test genetic counseling.,81425,CPT 81425 corresponds to clinical whole genome sequencing/reporting and is the appropriate code for WGS.,No,"Although indication, patient age, and ordering provider are acceptable, BCBS_FEP coverage requires prior standard cytogenetic testing (e.g., CMA) be nondiagnostic and documented pre‑test genetic counseling; those prior requirements are not met/documented, so WGS is not covered at this time.",1972,1964,3936
Case16126,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states BRCA1 and BRCA2 testing has been ordered.,Not Specified,BCBS FEP BRCA coverage is based on personal/family cancer risk criteria rather than an absolute age cutoff; no age-based exclusion for BRCA testing is specified that would preclude testing in an infant.,Not Specified,"BCBS FEP policies require ordering by a qualified provider but do not mandate a single specialty (e.g., gynecologist is an acceptable ordering clinician for BRCA testing); the record lists a gynecologist, which is not specifically disallowed, but the policy does not define a restrictive specialty requirement.",No,"BCBS FEP BRCA coverage requires specific personal or family history of breast/ovarian (or related) cancer or other high-risk clinical criteria. This infant presents with multiple congenital anomalies and no documented personal or family history of BRCA‑related cancers, so the medical indication criterion is not met.",Not Specified,"BCBS FEP BRCA testing criteria do not mandate prior genetic testing (e.g., FISH) as a prerequisite; although FISH was performed and nondiagnostic, there is no specified required prior test for BRCA testing.",No,"BCBS FEP BRCA eligibility depends on family cancer history. Although parental consanguinity is reported, there is no reported family history of breast/ovarian or BRCA‑related cancers; thus family-history criteria for BRCA testing are not met.",Yes,"BCBS FEP generally requires genetic counseling for BRCA testing. The record documents pre-test counseling completed and planned post-test follow-up with a genetic counselor, meeting counseling requirements.",81162,"Among the provided options, 81162 corresponds to BRCA1/BRCA2 testing (commonly used for BRCA duplication/deletion analysis or BRCA-related testing) and is the most appropriate code for BRCA1/2 testing from the list.",No,"Applying BCBS FEP BRCA coverage criteria: testing is covered only for individuals meeting defined personal/family cancer risk criteria. This 6‑week‑old infant with multiple congenital anomalies and no documented family history of BRCA‑related cancer does not meet medical-necessity criteria, so BRCA testing is not covered.",1967,2237,4204
Case4512,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) is being pursued to identify a potential genetic etiology.,Not Specified,BCBS FEP WGS/WES policies do not impose a strict age cutoff for diagnostic sequencing in suspected genetic disorders; no age-based exclusion is specified and the patient (21 y) does not raise an age-based eligibility issue.,Not Specified,"BCBS FEP policies typically do not mandate a specific ordering provider specialty (they require appropriate documentation and usually recommend genetics involvement). The record does note genetic counselor pre-test counseling, but the policy does not explicitly require a particular ordering provider type.",Yes,"BCBS FEP coverage criteria support diagnostic WGS/WES for patients with a suspected genetic etiology for congenital anomalies or major congenital malformations; the patient has a major congenital cardiac anomaly present since birth, which meets a defined clinical indication.",No,"BCBS FEP medical policy generally requires prior appropriate targeted testing (for example chromosomal microarray and/or targeted gene(s) or panel testing) before WGS/WES for many indications; the record states no prior genetic testing has been performed, so required prior tests are not completed.",Yes,"Family history is relevant to eligibility — record documents a sibling with a concerning brief resolved unexplained event suggesting a possible heritable predisposition, which is pertinent to genetic evaluation per BCBS FEP criteria.",Yes,"BCBS FEP policies require documentation of pre-test counseling for genomic sequencing; the record documents pre-test counseling with a genetic counselor and a planned post-test visit, meeting counseling requirements.",81425,The requested test is whole genome sequencing; CPT 81425 is the appropriate code for comprehensive genome sequencing/interpretation (WGS) per coding guidelines.,No,"Although the clinical indication and counseling meet BCBS FEP criteria for genomic sequencing, the policy requires prior appropriate testing (e.g., chromosomal microarray and/or targeted gene/panel testing) before authorization of WGS in this scenario; those prior tests have not been completed, so coverage would be denied pending required prior testing.",2006,1877,3883
Case1778,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) has been requested for diagnostic clarification.,Not Specified,Typical payer WES policies do not impose strict age cutoffs; the patient is 14 years old and age-based criteria are generally not specified for WES in standard coverage rules.,Not Specified,Most payer WES policies do not mandate a specific ordering provider specialty in the documented information; no provider specialty requirements are provided in the patient data.,No,"Common payer medical-necessity criteria for WES require multiple congenital anomalies, moderate-to-severe developmental delay/intellectual disability, or a suspected monogenic disorder after prior recommended testing. This patient has an isolated ocular coloboma (single congenital anomaly) with no documented developmental delay or syndromic features, so he does not meet the typical specific medical indications for WES.",No,"Payer policies commonly require prior appropriate targeted testing such as chromosomal microarray (CMA) or other recommended tests before WES for congenital anomalies. The record notes prior FISH was nondiagnostic but does not document CMA or other required prior testing, so required prior tests are not completed.",No,No family history or consanguinity is provided. Relevant payer criteria that consider family history for WES eligibility are not met because no such history is documented.,No,"Many payer policies require documentation of pre-test genetic counseling for WES. The patient information does not document genetic counseling or consent, so counseling requirements are not met.",81415,"CPT 81415 is the code typically used for exome sequencing (WES), which matches the requested test.",No,"Applying typical payer WES coverage rules: the patient lacks the specified medical indications (multiple anomalies or developmental delay), required prior testing (CMA) is not documented, and genetic counseling is not documented. Therefore the request does not meet common coverage criteria and would not be covered.",1935,1587,3522
Case14155,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been requested to assess genetic contributors to the child’s neurodevelopmental presentation.,Yes,"Cigna’s coverage criteria for genomic sequencing specify use for pediatric-onset neurodevelopmental disorders (e.g., ASD, global developmental delay). The patient is 7 years old, which meets pediatric age-related eligibility.",Yes,"Cigna allows ordering by an appropriate treating physician/specialist (e.g., neurologist) provided they can document the clinical indication and follow-up; the test was ordered by neurology, which meets typical provider requirements.",Yes,"Cigna’s medical necessity criteria include unexplained autism spectrum disorder/neurodevelopmental disorder as an indication for WGS/WES when seeking a genetic diagnosis. The child has ASD/neurodevelopmental concerns, meeting that clinical indication.",No,Cigna’s policy generally requires prior standard testing (at minimum chromosomal microarray and appropriate single-gene or Fragile X testing where indicated) before WES/WGS in non-critically ill pediatric patients; the record states no prior genetic testing has been performed.,Yes,There is a family history (maternal uncle with a severe immunologic disorder) raising concern for an inherited predisposition. This family history is relevant to the genetic evaluation and supportive of pursuing genetic testing per policy.,No,"Cigna’s policy requires documentation that pre-test genetic counseling was offered/occurred; the family explicitly declined pre-test genetic counseling, so counseling requirements are not met.",81425,The requested test is whole genome sequencing; CPT 81425 corresponds to whole genome sequencing (proband) and is the appropriate billing code for WGS.,No,"Although age, provider type and clinical indication are met, Cigna requires prior standard testing (e.g., chromosomal microarray and Fragile X as applicable) and documentation of pre-test genetic counseling; neither prior testing nor counseling were completed, so the request does not meet Cigna coverage criteria and would not be approved as submitted.",1989,2314,4303
Case13406,baseline,without_policy,iter2,WGS,The clinical note states whole genome sequencing (WGS) has been ordered by a medical geneticist.,Not Specified,UHC WES/WGS coverage criteria do not impose a strict age cutoff; testing is applied based on clinical presentation (pediatric age is acceptable). No explicit age-based exclusion applies to this 6‑week‑old.,Yes,"Policy requires an appropriate ordering clinician; the test is ordered by a medical geneticist, which meets provider requirements in UHC coverage criteria.",Yes,"UHC criteria consider unexplained global developmental delay/neurologic/developmental disorders as medical indications for WGS, and this infant has global developmental delay.",Yes,"UHC generally requires prior standard testing (e.g., chromosomal microarray) for developmental delay before WES/WGS; CMA was performed and nondiagnostic per the record.",Not Specified,Family history/consanguinity is not a required determinant in UHC WGS coverage for this indication; the sibling's brief resolved unexplained event is noted but is not defined as a qualifying family history criterion in policy.,Yes,"UHC coverage expects documentation of genetic counseling; pre‑test counseling was completed and post‑test follow up is planned, satisfying counseling requirements.",81425,CPT 81425 corresponds to whole genome sequencing (WGS) analysis and interpretation.,Yes,"Per UHC coverage criteria the patient meets medical indication (global developmental delay), required prior testing (nondiagnostic CMA), an appropriate ordering provider (medical geneticist), and counseling documentation — therefore WGS is covered.",2004,2095,4099
Case3581,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states BRCA1 and BRCA2 testing has been ordered.,Not Specified,Cigna BRCA coverage is driven by personal/family history of BRCA-associated cancers rather than a strict age cutoff; no age-based exclusion or requirement for BRCA testing is specified that would apply to this 69-year-old.,Not Specified,"Cigna does not specify a narrow specialty requirement for ordering BRCA testing (it must be ordered by a qualified provider), and the information only lists the ordering provider as a cardiologist; the policy does not restrict ordering to a specific specialty in this case.",No,"Cigna medical necessity for BRCA1/2 testing requires a personal or family history of BRCA-associated cancers (eg, breast, ovarian, pancreatic, or certain prostate cancers) or other defined high-risk criteria. The patient’s indication is a history of hearing/visual impairment and a sibling with a brief resolved unexplained event, which do not meet Cigna’s BRCA clinical indications.",Not Specified,"Cigna BRCA coverage does not require completion of specific prior genetic tests (the prior nondiagnostic FISH is irrelevant to BRCA eligibility), and no other prior-test prerequisite is specified for BRCA1/2 sequencing in this clinical context.",No,"Cigna’s family-history criteria for BRCA testing require relatives with BRCA-associated cancers. Although the patient has a sibling with an unexplained event, there is no family history of breast/ovarian/pancreatic/prostate cancer documented, so the specified family-history criteria are not met.",No,"Cigna’s BRCA testing policies expect documentation of pre-test genetic counseling or that testing be ordered in the context of appropriate counseling; the record states no pre-test genetic counseling was conducted, so counseling requirements are not met.",Not Specified,"The usual CPT codes for BRCA1 and BRCA2 sequencing (eg, gene-specific codes) are not among the provided choices; therefore the best-matching code cannot be selected from the offered list.",No,Under Cigna criteria BRCA1/2 testing is covered for individuals with qualifying personal or family history of BRCA-associated cancers and appropriate pre-test counseling. This patient lacks qualifying cancer history and pre-test genetic counseling; therefore the test is not covered.,1989,36217,38206
Case10529,baseline,without_policy,iter2,WES,The case explicitly states whole exome sequencing (WES) is being pursued with UHC coverage.,Yes,UHC WES policies specifically address pediatric patients with unexplained developmental delay/intellectual disability; the patient is 6 years old and therefore meets age-based pediatric eligibility.,Yes,"UHC requires ordering by an appropriate treating specialist or genetics provider; the referral is from neurology and the family has engaged genetics, meeting ordering/provider requirements.",Yes,UHC coverage criteria include unexplained developmental delay/intellectual disability as an indication for WES; the patient has nonsyndromic developmental delay and intellectual disability.,No,"UHC typically requires prior appropriate testing (eg, chromosomal microarray and fragile X testing) before WES. Fragile X was done and nondiagnostic, but no CMA is documented, so the required prior test (CMA) has not been completed.",Yes,Family history of neurologic disease (maternal uncle with dystonia and ataxia) is present and is relevant to the genetic evaluation and eligibility considerations.,Yes,UHC requires pre-test genetic counseling for WES; the family has seen a genetic counselor multiple times and pre-test counseling is complete with plans for post-test follow-up.,81415,"CPT 81415 corresponds to whole exome sequencing (proband), which matches the requested WES.",No,"Although age, clinical indication, provider, counseling, and family history meet UHC criteria, a required prior test (chromosomal microarray) is not documented as completed; absence of the required prior testing would render the WES request non-covered at this time.",1987,1594,3581
Case18821,baseline,without_policy,iter2,WES,The obstetrician explicitly requests fetal whole exome sequencing (WES) at 22 weeks' gestation.,Not Specified,BCBS FEP WES policies do not impose a strict age cutoff that would exclude prenatal/fetal testing; the patient is a fetus at 22 weeks and no age-based exclusion is applicable or specified.,Not Specified,BCBS FEP policies typically require an appropriate ordering clinician but do not universally restrict ordering to a single specialty in the documentation provided; the obstetrician (MFM/OB) ordering prenatal WES is commonly acceptable but no specific ordering-provider specialty requirement is documented here.,Yes,"Payer coverage criteria for WES include evaluation of multiple congenital anomalies/multisystem fetal anomalies to identify a genetic etiology; prenatal imaging shows multiple congenital anomalies affecting different organ systems, meeting a defined clinical indication.",No,"BCBS FEP typically requires prior standard testing (eg, chromosomal microarray and/or targeted chromosomal testing) before WES in the prenatal setting; the patient has no prior genetic testing documented.",Yes,Family history is relevant under coverage considerations; a maternal aunt reported to have dysmorphic features is present and is pertinent to genetic etiologic evaluation.,No,BCBS FEP WES coverage commonly requires documentation of pre-test genetic counseling for informed consent and appropriate test selection; there is no documentation of pre-test genetic counseling for this patient.,81415,"CPT 81415 corresponds to clinical whole exome sequencing (proband/exome sequencing), which best matches the requested fetal WES.",No,"Although the clinical indication (multisystem fetal anomalies) supports WES, BCBS FEP coverage requires completion of prior recommended testing (eg, chromosomal microarray) and documentation of pre-test genetic counseling; those prerequisites are not met, so the test is not covered as requested.",1991,1642,3633
Case5230,baseline,without_policy,iter2,WES,The clinical note explicitly states the patient was referred for whole exome sequencing (WES).,Not Specified,"UHC WES coverage criteria are driven by clinical indication rather than strict age cutoffs; the patient is 15 (adolescent) which is within typical covered age ranges, and the policy does not impose a specific age exclusion.",Not Specified,"UHC policies require ordering by an appropriate treating clinician but do not universally restrict ordering to a specific specialty in all cases; the patient was referred by neurology (an appropriate specialist), and the policy does not state a single mandatory ordering provider type.",Yes,UHC covers WES for individuals with unexplained congenital anomalies or suspected monogenic disorders when prior testing is nondiagnostic; the patient has a congenital anomaly and suspected genetic etiology.,Yes,UHC WES criteria require prior chromosomal microarray for congenital anomalies; the record documents a nondiagnostic CMA was completed.,Yes,"UHC considers relevant family history supportive of testing; the patient has a sibling with an inborn error of metabolism, which is relevant to WES consideration.",No,"UHC typically requires documentation of pre-test genetic counseling by a qualified provider; here genetic counseling was declined and no counseling documentation is provided, so counseling requirements are not met.",81415,CPT 81415 corresponds to clinical whole exome sequencing (proband-only exome) which matches the requested WES.,No,"Although clinical indications and prior testing meet UHC WES medical necessity criteria (congenital anomaly with nondiagnostic CMA and supportive family history), the required pre-test genetic counseling/documentation is not met (patient declined), therefore coverage criteria are not fully satisfied per UHC policy.",1953,1996,3949
Case6478,baseline,without_policy,iter2,BRCA1/2,The referral explicitly requests germline BRCA1 and BRCA2 testing for a man with metastatic prostate cancer.,Not Specified,UHC BRCA1/2 coverage criteria do not impose a specific age cutoff for germline BRCA testing in adults; the patient is an adult (52) but no age-based eligibility rule is specified in policy.,Not Specified,UHC medical policy requires an appropriate ordering clinician but typically does not restrict testing to a specific specialty in the BRCA coverage policy; the record shows a physician referral but no specialty restriction is specified.,Yes,UHC covers germline BRCA1/2 testing for individuals with a personal history of metastatic prostate cancer (a NCCN-recognized indication); the patient meets this clinical indication.,Not Specified,UHC BRCA coverage does not require prior genetic or tumor testing as a prerequisite to germline BRCA1/2 testing in this clinical scenario; no prior tests are mandated by policy.,Yes,Family history of a first‑degree relative with pancreatic cancer is relevant to BRCA testing per UHC criteria and is present (father with pancreatic cancer).,No,"UHC BRCA testing policy requires documentation of pre‑test genetic counseling or informed consent per policy; the patient did not receive pre‑test counseling (only plans for post‑test counseling), so counseling requirement is not met.",Not Specified,"The usual specific CPT codes for BRCA1 and BRCA2 (e.g., 81211 / 81213) are not among the provided options, so none of the listed codes clearly correspond to single‑gene BRCA1/2 testing.",No,"Although the patient meets clinical indication (metastatic prostate cancer) and has relevant family history, UHC requires pre‑test genetic counseling/documentation for BRCA1/2 coverage and this was not completed prior to ordering; therefore coverage criteria are not fully met.",1976,1977,3953
Case13613,baseline,without_policy,iter2,WES,The clinical note explicitly states whole exome sequencing (WES) was requested to assess fetal anomalies.,Not Specified,UHC WES criteria are phenotype-driven (multiple congenital anomalies/neurodevelopmental issues) rather than age-limited; the patient is a fetus but no age-based exclusion is specified in the payer criteria.,Yes,"UHC typically requires ordering/authorization involvement by or discussion with a genetics provider for WES; the record documents pre-test discussion with a genetic specialist, satisfying provider requirements.",Yes,"UHC indications for WES include multiple unexplained structural congenital anomalies; fetal imaging identified multiple structural anomalies, meeting medical indication criteria.",No,"UHC generally requires prior standard testing (eg, chromosomal microarray / karyotype) before WES in prenatal cases; the record notes only Fragile X testing (nondiagnostic) and does not document CMA or cytogenetic testing.",Yes,Family history of dysmorphic features in a maternal aunt is documented; payer criteria consider relevant family history (similar phenotype/affected relatives) supportive for WES eligibility.,Yes,"UHC requires pre-test genetic counseling for genome/exome testing; the record documents pre-test discussion with a genetic specialist, meeting counseling requirements.",81415,The requested test is whole exome sequencing; the appropriate CPT for clinical exome sequencing (interpretation/report) is 81415.,No,"Although medical indication, genetic counseling, and genetics-provider involvement are met, coverage is contingent on completion of required prior cytogenetic testing (eg, chromosomal microarray), which is not documented; therefore the request does not meet all UHC prior-test requirements for approval.",1978,1474,3452
Case5380,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) is requested to assess for an underlying genetic cause.,Not Specified,UnitedHealthcare WES/WGS coverage is driven by clinical indications rather than a strict age cutoff in typical policy language; no explicit age-based exclusion or minimum is stated for WGS in this clinical context.,Not Specified,"UHC policies typically require an appropriate ordering clinician but do not universally restrict orders to a single specialty; the patient was referred by neurology (an appropriate specialist), but the payer policy does not explicitly mandate a single named specialty in the provided information.",Yes,The infant has early-onset recurrent seizure-like events/BRUE with concern for genetic etiology and prior nondiagnostic CMA — this meets UHC criteria for WES/WGS for unexplained early-onset epilepsy/neurodevelopmental disorder.,Yes,"UHC generally requires prior chromosomal microarray evaluation before WES/WGS when applicable; the record states CMA was performed and nondiagnostic, satisfying that prior-test requirement. (No documentation of a prior epilepsy gene panel is provided.)",No,Family history provided only includes maternal short stature (a growth finding) which is not a clearly relevant family history of seizures or a specified consanguinity criterion in UHC coverage rules.,No,"UHC typically requires documentation of pre-test genetic counseling or informed consent; the family declined pre-test genetic counseling, so the counseling requirement is not met.",81425,"CPT 81425 corresponds to whole genome sequencing (interpretation and report), which matches the requested WGS.",No,"Although clinical indications for WGS are met and prior CMA is nondiagnostic, the payer routinely requires documented pre-test genetic counseling/informed consent. The family declined pre-test counseling, so coverage would not meet UHC documentation requirements and would be denied.",1981,2339,4320
Case15570,baseline,without_policy,iter2,BRCA1/2,The clinician explicitly requested BRCA1 and BRCA2 testing per the patient information.,No,"BCBS FEP BRCA coverage is oriented to adult-onset hereditary breast/ovarian cancer indications and generally disfavors predictive testing in minors absent a clear, actionable childhood management change. The patient is 15 and has no qualifying personal/family cancer history, so age-related (minor) considerations are not met.",Not Specified,"BCBS FEP policy does not mandate a specific ordering provider specialty for BRCA testing (it does require appropriate documentation of indications and counseling), and the record only documents a general pediatrician order—policy does not explicitly prohibit this.",No,"Coverage criteria require personal or family history meeting hereditary breast/ovarian cancer guidelines (e.g., breast/ovarian cancer in proband or close relatives, known familial pathogenic variant). The patient has Hirschsprung disease and no family cancer history, so no defined medical indication is met.",Not Specified,BCBS FEP BRCA coverage does not require prior cytogenetic testing (karyotype) or other prior tests before ordering BRCA sequencing; the nondiagnostic karyotype is irrelevant to BRCA coverage criteria.,No,"Family-history criteria are specified for BRCA testing under BCBS FEP, and the record documents no family cancer history (mother has bipolar disorder only), so the patient does not meet family-history criteria.",No,"BCBS FEP expects documentation of pre-test genetic counseling for BRCA testing. There is no documentation of pre-test counseling in the record, so counseling requirements are not met.",Not Specified,The standard single-gene BRCA1/2 CPT codes (sequencing) are not among the provided code options; therefore the best matching CPT code from the supplied list cannot be specified.,No,"Under BCBS FEP criteria, BRCA testing is not medically necessary here: the patient is a minor without qualifying personal or family history of HBOC, and required pre-test counseling is not documented. Therefore the test is not covered.",1979,2514,4493
Case5834,baseline,without_policy,iter2,CMA,The referral explicitly requests chromosomal microarray (CMA) testing to evaluate a genomic etiology for the patient's developmental disorder.,Not Specified,BCBS FEP CMA coverage is based on clinical indication (unexplained developmental delay/intellectual disability) and does not impose a strict age cutoff; the policy does not specify age-based exclusion for CMA.,Not Specified,BCBS FEP CMA policy does not mandate a specific ordering provider specialty in the documentation provided; no specialty requirement is indicated in the patient information.,Yes,Patient has lifelong severe intellectual disability (diagnosed by age 18) consistent with unexplained intellectual disability/developmental disorder—an indicated clinical reason for CMA per BCBS FEP medical policy.,Not Specified,BCBS FEP considers CMA a first‑tier test for unexplained ID/DD and does not require completion of other specific genetic tests beforehand; the patient has no prior testing but none is mandated.,Not Specified,BCBS FEP CMA coverage is driven by the proband's clinical presentation (ID/DD); family history/consanguinity criteria are not specified for CMA eligibility here (mother's ovarian cancer is not relevant).,Yes,"When required/expected by payer policy, documentation of pre‑test genetic counseling is requested; the patient completed pre‑test counseling with a genetic counselor and post‑test follow‑up plans were discussed, meeting counseling expectations.",81228,"CPT 81228 corresponds to chromosomal microarray analysis (CMA), which is the test requested.",Yes,"Patient meets clinical indication for CMA (unexplained severe intellectual disability), counseling was completed, no disqualifying age or prior‑test requirements apply under BCBS FEP policy; therefore CMA is covered.",2002,1746,3748
Case1501,baseline,without_policy,iter2,WES,The case text explicitly states 'Whole exome sequencing (WES) is being ordered.',Yes,Payer criteria (UHC) permit WES for pediatric patients with unexplained developmental delay and multiple congenital anomalies; the patient is 2 years old and meets pediatric age indication.,Not Specified,"The record says the child was referred by a developmental pediatrician and WES is being ordered, but it does not state whether the order is by a clinical geneticist or otherwise meets any explicit ordering-provider requirement in UHC policy.",Yes,"UHC covers WES when there is unexplained developmental delay/intellectual disability or multiple congenital anomalies after prior testing; the patient has multiple congenital anomalies and ongoing developmental concerns, meeting the clinical indication.",No,"UHC generally requires prior recommended cytogenomic testing such as chromosomal microarray (CMA) (and other condition-appropriate targeted tests) before WES; only a nondiagnostic karyotype is documented, not CMA.",Not Specified,"While a maternal history of Long QT syndrome is noted, UHC WES criteria do not require specific family history/consanguinity for coverage of WES in this clinical scenario, and no family-criteria requirement is specified here.",Yes,"UHC requires pre- and post-test genetic counseling for WES; pre-test counseling was completed and post-test follow-up is planned, satisfying counseling requirements.",81415,CPT 81415 corresponds to clinical whole exome sequencing (proband/standard exome) and is the appropriate code for WES.,No,"Although the patient meets age, clinical indication, and counseling requirements, required prior testing (notably chromosomal microarray) has not been documented; under UHC coverage rules WES would therefore not be approved until prior testing requirements are met.",1975,2015,3990
Case10427,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) is being requested.,Yes,"UnitedHealthcare pediatric genomic testing criteria apply to children; the patient is an 8-week-old infant (pediatric), meeting age-based eligibility for WGS per payer pediatric testing policy.",Yes,"UHC allows ordering by treating specialists (e.g., neurologist) and/or genetics teams; the test was referred by a neurologist and counseling was provided by a genetic counselor, satisfying ordering/counseling provider requirements.",Yes,"Clinical indications listed in UHC criteria for WGS/WES include unexplained hypotonia and suspected genetic neurologic disorders; the infant has significant hypotonia and a positive family history, meeting medical necessity criteria.",No,"UHC generally requires prior first‑tier testing (chromosomal microarray) or documentation why first‑tier testing is not appropriate; only FISH was performed and was nondiagnostic, and no CMA result is documented, so required prior testing has not been completed.",Yes,"Family history is relevant: an older sibling had unexplained developmental regression, which supports testing per UHC family-history/clinical criteria for genetic evaluation.",Yes,"Pre-test genetic counseling was completed with a genetic counselor multiple times and post-test follow-up is planned, meeting UHC counseling requirements for clinical genomic testing.",81425,CPT 81425 corresponds to whole genome sequencing (proband) and best matches the requested WGS.,No,"Although age, indication, provider, family history, and counseling meet UHC criteria, coverage requires documented prior first‑tier testing (typically chromosomal microarray) or an exception; only FISH was nondiagnostic and no CMA is documented, so coverage would be denied pending required prior testing or justification.",1993,1554,3547
Case8485,baseline,without_policy,iter2,WES,The patient summary explicitly states 'whole exome sequencing (WES) has been ordered.',Not Specified,Cigna WES coverage criteria do not impose a strict age cutoff for pediatric WES; the patient is 8 years old but the policy does not specify an age-based exclusion or specific age requirement.,Not Specified,"Cigna's WES policy emphasizes ordering by a clinician familiar with genetic testing and interpretation, but it does not rigidly restrict ordering to a single listed specialty in all cases; the record only notes a general pediatrician as the ordering provider, and the policy language about required ordering provider specialty is not definitive in the provided information.",Yes,"Per Cigna criteria, WES is indicated for unexplained neurodevelopmental disorders (developmental delay, hypotonia, evolving tone abnormalities); the patient's persistent motor delay and hypotonia since infancy meet those medical indication criteria.",No,"Cigna typically requires first‑tier testing (e.g., chromosomal microarray and Fragile X where applicable) prior to WES. Although Fragile X testing was nondiagnostic, there is no documentation that a CMA/microarray was completed, so required prior testing is incomplete.",Not Specified,"While a family history (sibling with ASD) is reported, Cigna's principal WES eligibility is driven by the proband's clinical phenotype and prior testing; family history/consanguinity is not defined as a required criterion in the policy context provided.",No,"Cigna requires documentation of pre‑test genetic counseling/consent for WES and discussion of possible incidental/secondary findings; pre-test genetic counseling was not performed per the record, so counseling requirements are not met.",81415,CPT 81415 corresponds to exome sequencing (WES) with bioinformatic analysis and interpretation and is the appropriate billing code for the requested test.,No,"Although the clinical indication (unexplained hypotonia and developmental delay) supports WES per Cigna policy, coverage prerequisites are unmet: required prior testing (chromosomal microarray) is not documented and pre‑test genetic counseling/documentation was not completed. Therefore the request would not meet Cigna coverage requirements as submitted.",1971,1773,3744
Case11795,baseline,without_policy,iter2,WES,The clinical note explicitly states that whole exome sequencing (WES) is being ordered after a nondiagnostic chromosomal microarray.,Yes,"BCBS_FEP WES coverage specifies pediatric/infant indications (e.g., neonates/infants with suspected genetic disorders, congenital/early-onset disease). The patient is a 3‑week‑old infant, which meets the payer's age‑based pediatric eligibility.",Not Specified,"BCBS_FEP policy requires ordering by an appropriate treating clinician but does not rigidly restrict to a single specialty; the record shows referral by a cardiologist but the policy does not mandate a specific specialty credential, so explicit specialty requirement is not specified.",Yes,"Medical necessity criteria for WES under BCBS_FEP include infants with suspected genetic conditions (e.g., channelopathies, cardiomyopathy, significant arrhythmia) and nondiagnostic prior testing; the infant has an abnormal ECG concerning for channelopathy/arrhythmia/cardiomyopathy, meeting a defined clinical indication.",Yes,"BCBS_FEP generally requires prior standard testing (chromosomal microarray) for pediatric neurodevelopmental/ congenital indications before WES; CMA was previously performed and was nondiagnostic, satisfying the required prior test criterion.",Yes,"Family history can be a supporting criterion in BCBS_FEP WES decisions. The patient has a sibling with moderate–severe intellectual disability diagnosed in childhood, which is relevant and supportive of testing.",Yes,"BCBS_FEP WES policy requires documented pre‑test genetic counseling and post‑test follow‑up plans. The record documents pre‑test genetic counseling with plans for post‑test follow‑up, meeting this requirement.",81415,CPT 81415 corresponds to clinical exome sequencing (proband only) and is the correct code for whole exome sequencing as ordered.,Yes,"Under BCBS_FEP criteria, WES is covered for pediatric patients with suspected genetic conditions when prior CMA is nondiagnostic, clinical indications (suspected channelopathy/arrhythmia/cardiomyopathy) are present, pre‑test counseling is documented, and family history supports a genetic etiology. All these coverage criteria are met.",2021,1775,3796
Case2007,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states the patient was referred for BRCA1 and BRCA2 testing.,Yes,"BCBS_FEP policies require adult-age eligibility (and often a minimum age of 18 for predictive/diagnostic testing); the patient is 18, meeting age-based requirements for BRCA testing.",Yes,"BCBS_FEP allows ordering by a treating physician; the order was placed by a family medicine physician, which meets typical ordering-provider requirements.",Yes,"Medical necessity criteria include a personal history of breast cancer and/or a first-degree relative with breast cancer at ≤50. The patient has metastatic breast cancer and a mother diagnosed at ≤50, satisfying clinical indications in BCBS_FEP BRCA policy.",Not Specified,BCBS_FEP BRCA coverage does not mandate prior chromosomal microarray or other specific genetic tests before BRCA1/2 testing; the prior nondiagnostic CMA is not a required prerequisite.,Yes,"Family-history criteria are specified for BRCA coverage and the patient has a relevant family history (mother with breast cancer at age ≤50), which supports eligibility.",Yes,"BCBS_FEP typically requires documentation of genetic counseling. The patient completed pre-test counseling and will return for post-test counseling, meeting counseling requirements.",81228,"Of the provided CPT options, 81228 most closely corresponds to BRCA1/BRCA2 gene testing in standard coding lists; therefore it is the best match for BRCA1/2 testing among the choices.",Yes,"Based on BCBS_FEP criteria (personal history of breast cancer, first-degree relative with early-onset breast cancer, appropriate counseling completed, appropriate ordering provider and age), BRCA1/2 testing is medically necessary and covered.",1980,2385,4365
Case7297,baseline,without_policy,iter2,WES,Patient record explicitly states whole exome sequencing (WES) is being pursued.,Not Specified,UHC WES coverage criteria do not impose strict age cutoffs for symptomatic individuals; the patient is 3 years old and age-based restrictions are not specified in the policy.,Not Specified,UHC policies generally require documentation of genetic counseling and an ordering clinician but do not mandate a specific ordering provider specialty; the record shows referral by family medicine and pre-test counseling by a genetics specialist.,Yes,UHC covers WES for individuals with unexplained multiple congenital anomalies or multisystem involvement when prior diagnostic testing is nondiagnostic; this 3-year-old has multiple congenital anomalies and a nondiagnostic karyotype.,No,UHC requires appropriate prior testing (typically chromosomal microarray) before WES for multisystem congenital anomalies; only a nondiagnostic karyotype is documented and CMA is not documented as completed.,Not Specified,Family-history/consanguinity rules for WES are not specifically applied here; the noted maternal aunt with ovarian cancer is not a directly relevant affected relative for the patient's congenital anomaly indication and payer criteria do not hinge on that history.,Yes,UHC requires documentation of genetic counseling for WES; the record documents pre-test counseling with a genetics specialist and plans for post-test follow-up.,81415,"CPT 81415 corresponds to clinical whole exome sequencing (proband), which matches the requested test (WES).",No,"Although the patient meets the clinical indication and genetic counseling requirements, UHC requires prior appropriate diagnostic testing (e.g., chromosomal microarray) before WES for multisystem congenital anomalies; CMA is not documented, so coverage would not be approved until prior-test requirements are satisfied.",1997,1812,3809
Case2666,baseline,without_policy,iter2,BRCA1/2,The patient is explicitly undergoing BRCA1/2 testing per the clinical information (ordered by her obstetrician).,Yes,BCBS FEP BRCA policies apply to adults; the patient is 21 years old and thus meets age-based eligibility (adult) for germline BRCA testing.,Not Specified,"The provided payer-level requirements do not strictly require a particular ordering specialty; although genetic counseling was completed (which supports appropriateness), the policy does not mandate a specific provider specialty for ordering.",Yes,"Medical indication criteria for BRCA testing include a first‑degree relative with metastatic prostate cancer (strong family history). The patient’s father has metastatic prostate cancer, satisfying a covered family-history indication.",Not Specified,There are no required prior diagnostic genetic tests for germline BRCA testing in this context; the prior nondiagnostic FISH is irrelevant to BRCA germline testing and the policy does not mandate other prior tests.,Yes,"Family-history criteria are specified for BRCA testing and the patient has a relevant family history (father with metastatic prostate cancer, a first‑degree relative).",Yes,"BCBS FEP BRCA testing generally expects documented pre-test genetic counseling; the record states pre-test counseling was completed with a genetic specialist and post-test follow-up is planned, meeting counseling requirements.",Not Specified,"None of the provided CPT options clearly correspond to standard BRCA1/2 germline testing CPT codes (BRCA1/2 are typically reported with 81211–81217 or gene-specific codes not listed), so a best-match code is not available among the choices.",Yes,Based on FEP BRCA coverage criteria the patient is an adult with a first-degree relative with metastatic prostate cancer and has documented pre-test genetic counseling; these elements meet policy criteria for coverage of germline BRCA1/2 testing.,1980,2090,4070
Case13983,baseline,without_policy,iter2,WGS,The patient information explicitly states 'whole genome sequencing (WGS) is being pursued.',Yes,"BCBS_FEP pediatric WGS criteria apply to infants/children with suspected genetic disorders; the patient is a 7‑week‑old infant, which meets age-based pediatric eligibility.",No,"BCBS_FEP policies require ordering by an appropriate specialist (e.g., clinical geneticist or treating specialist) or documentation of specialist/genetics oversight; the order was placed by a gynecologist and no documentation that the ordering provider meets the specialist requirement is provided.",Yes,"BCBS_FEP allows WGS when a suspected genetic disorder is present (e.g., unexplained concerning cardiac findings/channelopathy, abnormal ECG, family history) and prior relevant testing is nondiagnostic; the patient has an abnormal ECG, concern for channelopathy/arrhythmia, and a family history, meeting medical indication criteria.",No,"BCBS_FEP typically requires prior appropriate targeted testing (e.g., chromosomal microarray for developmental concerns and/or targeted cardiac gene panel) or documentation that such testing is not diagnostic or not appropriate; only prior FISH (nondiagnostic) is documented and CMA/targeted cardiac panel are not reported as completed.",Yes,BCBS_FEP considers relevant family history in eligibility for genomic testing; the maternal uncle's unexplained developmental regression is a relevant family history supporting inherited etiology.,Yes,BCBS_FEP requires pre‑test genetic counseling for comprehensive genomic testing; the record states pre‑test counseling was completed with a genetic counselor and plans for post‑test follow‑up are in place.,81425,CPT 81425 corresponds to clinical whole genome sequencing (proband or interpretation/report) and best maps to the requested WGS.,No,"Although the medical indication, age, family history, and genetic counseling meet BCBS_FEP criteria, required prior testing (e.g., CMA and/or targeted cardiac gene panel) was not documented and the ordering provider does not meet the stated specialist/provider requirement; because these payer‑specified prerequisites are not satisfied, coverage would be denied.",2045,1883,3928
Case15458,baseline,without_policy,iter2,BRCA1/2,Patient is being evaluated explicitly for BRCA1 and BRCA2 testing per the clinical note.,Yes,BCBS_FEP BRCA coverage includes individuals with a personal history of breast cancer at a young age; patient is 19 years old which meets age-related criteria for germline BRCA testing.,Yes,"BCBS_FEP permits ordering by licensed treating clinicians; the test was ordered by a nurse practitioner, which meets typical ordering provider requirements when documentation and counseling are provided.",Yes,Patient has a qualifying medical indication under BCBS_FEP BRCA criteria: personal history of breast cancer at a very young age and a family history of ovarian cancer and prostate cancer (suggestive of hereditary breast/ovarian cancer syndrome).,Not Specified,BCBS_FEP BRCA coverage does not mandate prior diagnostic tests such as FISH before germline BRCA testing; the nondiagnostic FISH is not a required prior test for BRCA germline analysis.,Yes,BCBS_FEP criteria consider family history of ovarian cancer and relevant male cancers (prostate) as qualifying; the patient has such family history (maternal aunt with ovarian cancer and a relative with metastatic/ductal prostate cancer).,Yes,"BCBS_FEP requires documentation of pre-test genetic counseling for hereditary cancer testing; the patient completed pre-test counseling with plans for post-test follow-up, satisfying counseling requirements.",81277,"The requested test is germline BRCA1/2 analysis by sequencing; CPT 81277 corresponds to BRCA1/BRCA2 sequence analysis (primary code for BRCA sequencing), while 81162 would represent separate large rearrangement/duplication analysis if ordered in addition.",Yes,"Based on BCBS_FEP coverage criteria the patient meets age, clinical indication, family-history, counseling, and ordering-provider requirements for BRCA1/2 germline testing, so the test is covered.",1991,2228,4219
Case18868,baseline,without_policy,iter2,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been ordered to assess for an underlying hereditary cancer predisposition.,Not Specified,Cigna WGS/WES policies do not impose a specific age cut-off for testing in adults with suspected genetic disorders; the patient is 41 but no age-based eligibility criterion in the provided payer rules applies.,Yes,"Cigna typically requires ordering/authorization by an appropriate genetics professional for advanced genomic testing; the request was made after evaluation by a medical geneticist, so provider requirements are met.",No,"Cigna's WGS/WES coverage criteria specify narrow indications (e.g., undiagnosed developmental or multiple congenital anomaly syndromes, often in pediatrics) and generally do not list adult hereditary cancer predisposition as an accepted indication for WGS; the patient’s indication (adult primary peritoneal carcinoma for hereditary cancer evaluation) does not meet those specific WGS indications.",No,"Cigna policies require prior appropriate targeted testing (e.g., guideline-based hereditary cancer gene panel testing and other specified prior tests) before WGS; the record shows only a nondiagnostic karyotype and no prior targeted hereditary cancer gene panel, so required prior testing is not documented.",Not Specified,"While family history is clinically relevant (mother with a severe hematologic disorder), Cigna's WGS coverage criteria do not specify family history/consanguinity as a standalone eligibility criterion for WGS in adult hereditary cancer evaluation in the provided policy framework.",No,"Cigna requires appropriate pre-test genetic counseling/documentation for hereditary genomic testing; the materials provided include no documented pre-test genetic counseling, so counseling requirements are not met.",81425,"The requested test is whole genome sequencing; CPT 81425 corresponds to genome sequencing (eg, WGS) and is the appropriate code among the options.",No,"Applying Cigna policy: WGS for adult hereditary cancer predisposition is not an accepted indication; required prior targeted testing is not documented and pre-test genetic counseling is lacking. Although ordered by a medical geneticist, the request does not meet Cigna WGS coverage criteria, so the test is not covered.",1989,1955,3944
Case10917,baseline,without_policy,iter2,WES,"The clinical note explicitly states ""whole exome sequencing (WES) has been ordered.""",Not Specified,"UHC WES coverage criteria are based on clinical indications (e.g., multiple congenital anomalies, unexplained pediatric presentations) rather than a strict age cutoff; no specific age-based exclusion/requirement is stated and the infant age (8 weeks) does not conflict with pediatric indications.",Yes,"UHC requires that WES be ordered/evaluated by a qualified genetics professional or with genetics involvement; the patient was evaluated and the test ordered by a medical geneticist, satisfying ordering/provider requirements.",Yes,"UHC covers WES for individuals with suggestive clinical presentations such as multiple congenital anomalies or otherwise unexplained suspected genetic disorders. The infant has persistent conjugated hyperbilirubinemia (unexplained cholestasis) and a family history of an affected sibling with multiple congenital anomalies, meeting a medical indication for WES.",No,"UHC generally requires appropriate prior testing (e.g., chromosomal microarray for multiple congenital anomalies and targeted testing as clinically indicated) before WES; the record documents prior Fragile X testing only and does not document completion of CMA or other recommended prior testing.",Yes,"Family-history criteria are relevant for WES under UHC policies, and this patient has an older sibling with multiple congenital anomalies, which is directly relevant to eligibility.",Yes,"UHC requires pre-test genetic counseling for WES; the record states pre-test counseling was completed with a genetic specialist, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (sequencing and interpretation of the exome), which matches the ordered WES.",No,"Although clinical indications, genetics provider involvement, counseling, and relevant family history support medical necessity per UHC, required prior testing (notably chromosomal microarray or other indicated targeted testing) is not documented; per UHC coverage rules lack of required prior tests typically renders WES not covered at this time.",1984,1799,3783
Case12792,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states the 12-year-old was referred for BRCA1/2 testing.,No,BCBS_FEP BRCA coverage criteria are age-sensitive: testing is for individuals with personal or strong family histories of hereditary breast/ovarian cancer and predictive testing for adult-onset conditions is generally deferred until adulthood; the patient is 12 years old and does not meet age-related criteria.,Not Specified,"The provided payer criteria do not explicitly restrict BRCA ordering to a specific specialty; a family medicine physician referred the patient and pre-test counseling was completed, but no BCBS_FEP-specific ordering-provider specialty requirement is documented in the case information.",No,"BCBS_FEP BRCA medical indications require a personal history of relevant cancers or a family history meeting high-risk criteria. The patient has congenital choanal atresia and an unspecified maternal growth abnormality, which do not meet BRCA indication criteria.",Not Specified,BCBS_FEP BRCA coverage does not mandate prior diagnostic tests (FISH is unrelated to BRCA) and no specific prior-testing prerequisite for BRCA1/2 was documented in the patient information.,No,"Coverage criteria rely on family history of breast/ovarian cancer or known familial BRCA pathogenic variant; the only family detail provided is a maternal growth abnormality, which is not a qualifying family history.",Yes,"BCBS_FEP typically requires documentation of pre-test genetic counseling for BRCA testing; the record states pre-test genetic counseling was completed and post-test follow-up is planned, satisfying counseling requirements.",81277,"Of the provided CPT options, 81277 corresponds to BRCA-related gene testing (represents BRCA1/2 targeted testing/large rearrangement analysis) and is the best match for a BRCA1/2 test.",No,"Per BCBS_FEP criteria, BRCA1/2 testing is not covered for an asymptomatic child without a qualifying personal or family history of hereditary breast/ovarian cancer; the patient is 12 years old with no relevant family history, so coverage is not met despite documented counseling.",1963,1821,3784
Case8710,baseline,without_policy,iter2,WES,The note explicitly states whole exome sequencing (WES) has been requested to investigate a genetic etiology for autism spectrum disorder.,Not Specified,UnitedHealthcare WES coverage is driven by clinical indication (developmental/neurologic disorders) rather than strict age cutoffs; no age-based exclusion applies to this 12-year-old in applicable policy.,Not Specified,"UHC policies focus on clinical indications and testing pathway; they do not universally restrict ordering to a single specialty in the provided criteria, and the record shows referral by a developmental pediatrician (an appropriate specialist), but specific ordering-provider requirements are not specified in the available policy context.",Yes,"UHC permits WES for unexplained autism spectrum disorder when there is an additional abnormality/other organ system involvement or neurodevelopmental disorder; the patient has ASD plus at least one additional abnormality, meeting the medical indication.",No,"UHC generally requires prior appropriate testing (typically chromosomal microarray and other targeted testing such as fragile X as clinically indicated) before WES; only karyotype was performed and was nondiagnostic, and no CMA or other required prior testing is documented.",Not Specified,"While family history (paternal uncle with dystonia/ataxia) is documented and may be supportive, UHC WES criteria do not make family history/consanguinity a required eligibility criterion in this context.",No,"UHC expects documentation of pre-test genetic counseling/informed consent for WES; no pre-test genetic counseling is documented in the record, so counseling requirement is not met.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (proband or single exome analysis), which matches the requested WES.",No,"Although the clinical indication is met (ASD with additional abnormality), coverage prerequisites per UHC (documentation of prior CMA/other required genetic testing and documented pre-test genetic counseling) are not satisfied; therefore the test would not be approved as submitted.",1991,1861,3852
Case16246,baseline,without_policy,iter2,BRCA1/2,The clinical note explicitly states she is being referred for BRCA1 and BRCA2 testing.,Yes,"UHC BRCA coverage includes women with personal history of breast cancer diagnosed before age 50; the patient is 35, so she meets the age-based criterion.",Yes,UHC allows ordering by the treating physician or appropriate clinician; the test was ordered/referral made by the patient's gynecologist (an appropriate ordering physician).,Yes,UHC defines medical indications including personal history of breast cancer diagnosed <50 years — the patient meets this specific medical indication.,Not Specified,"UHC BRCA germline testing criteria do not generally mandate completion of prior genetic tests (the prior nondiagnostic karyotype is not a required prerequisite), and no specific prior-test requirement is stated in the provided information.",Yes,"Family history criteria are relevant for BRCA testing; the patient reports an uncle with pancreatic cancer, which is a cancer type included in BRCA-associated family histories and therefore relevant to eligibility.",No,"UHC BRCA policy requires documentation of pre-test genetic counseling or informed discussion per policy; the record states no pre-test genetic counseling has been conducted, so counseling requirements are not met.",Not Specified,"The request is for BRCA1/2 germline testing, but the typical BRCA CPT codes (e.g., individual BRCA sequencing/deletion-duplication codes) are not among the provided options, so none of the listed codes clearly correspond.",No,"Although the patient meets age and medical indication criteria and the ordering provider is appropriate per UHC policy, pre-test genetic counseling/documentation is required per UHC BRCA coverage rules and has not been performed; therefore coverage would not be approved until counseling/documentation is completed.",1974,2392,4366
Case14017,baseline,without_policy,iter2,WES,The case states 'whole exome sequencing (WES) has been ordered' explicitly.,Not Specified,BCBS FEP WES coverage criteria are not typically age‑restricted for infants with suspected genetic neurologic disease; no specific age cutoff is provided in the information given.,Not Specified,The provided patient information does not state any payer requirement limiting which specialty may order WES; BCBS FEP policies generally do not mandate a single specific ordering provider type in the supplied facts.,Yes,"BCBS FEP considers WES medically reasonable for infants with early‑onset, unexplained seizure‑like events or suspected genetic neurologic disorders; this 7‑week‑old has recurrent seizure‑like events/BRUE and a family history of neurologic disease, meeting a clinical indication for WES.",No,"BCBS FEP commonly requires prior standard cytogenetic/microarray testing (chromosomal microarray) or other indicated prior testing to be nondiagnostic before WES for many neurodevelopmental/genetic indications. Only a karyotype (not CMA) is reported as nondiagnostic, so required prior testing (CMA) has not been documented as completed.",Yes,Family history is relevant per payer criteria for genetic testing: a maternal uncle with a movement disorder (dystonia and ataxia) is a positive family neurologic history that supports genetic evaluation.,Yes,"BCBS FEP typically requires documentation of pre‑test genetic counseling for WES; the record states pre‑test genetic counseling was completed with plans for post‑test follow‑up, satisfying counseling requirements.",81415,CPT 81415 corresponds to exome sequencing (whole exome sequencing) and is the appropriate code for WES.,No,"Although clinical indications, family history, and pre‑test counseling are present, BCBS FEP criteria generally require prior appropriate cytogenomic testing (chromosomal microarray) to be nondiagnostic before approving WES for many neurologic/genetic indications. Only a karyotype (not CMA) is documented; because the required prior test (CMA) has not been completed, coverage would not be approved as submitted.",2004,2089,4093
Case5674,baseline,without_policy,iter2,WES,Team plans whole exome sequencing (WES) to investigate a possible genetic epilepsy syndrome (explicitly stated).,Not Specified,BCBS_FEP WES policy does not impose strict age cutoffs for exome sequencing; pediatric patients are commonly eligible and no age restriction is noted in the provided clinical context.,Not Specified,The clinical information documents involvement of genetics for counseling and follow-up but does not indicate a payer-mandated ordering-provider restriction; BCBS_FEP policies typically do not rigidly require a specific ordering specialty in all cases.,Yes,"Patient has persistent, unexplained pediatric-onset seizures concerning for a genetic epilepsy syndrome and prior diagnostic workup (see Q4) — this meets BCBS_FEP clinical indications for WES when a genetic etiology is suspected.",Yes,"BCBS_FEP generally requires prior clinically appropriate testing such as chromosomal microarray for neurodevelopmental/epileptic presentations; a CMA was completed and was nondiagnostic, satisfying that prior-test criterion documented here.",Yes,"There is a relevant family history (uncle with sudden unexplained death before age 35), which supports suspicion of an inherited disorder and is relevant under payer criteria for expanded genetic evaluation.",Yes,"BCBS_FEP WES coverage requires appropriate genetic counseling; the patient had multiple visits with a genetic counselor and arranged post-test genetics follow-up, meeting counseling requirements.",81415,"CPT 81415 corresponds to whole exome sequencing (proband or single exome), which matches the requested WES.",Yes,"Under BCBS_FEP coverage logic the patient meets clinical indication (pediatric persistent unexplained seizures), has required prior testing (nondiagnostic CMA), has documented genetic counseling and follow-up arrangements, and has relevant family history — overall supporting coverage of WES.",1978,2143,4121
Case9773,baseline,without_policy,iter2,CMA,The clinical note explicitly states chromosomal microarray (CMA) was ordered to assess for genomic copy number changes.,Not Specified,FEP/CMA coverage is not age‑restricted in practice for evaluation of unexplained developmental delay/intellectual disability; no specific age cutoff is specified and the 2‑year‑old is within typical indication.,Not Specified,FEP policies for CMA do not mandate a specific ordering provider specialty (any qualified physician may order); the ordering oncologist is an appropriate ordering provider and no specialty restriction is specified.,Yes,"Medical necessity criteria for CMA under FEP include unexplained developmental delay/intellectual disability; the patient has severe intellectual disability, which meets this indication.",Not Specified,CMA is considered a first‑tier test for unexplained intellectual disability and there are no required prior genetic tests documented; patient has no prior genetic testing but none is required by policy.,Not Specified,"FEP CMA criteria do not require a specific family history; although a maternal aunt has an immunologic disorder noted, this is not a clearly defined family history requirement for CMA eligibility in the policy.",Not Specified,"FEP coverage for CMA does not uniformly mandate documented genetic counseling as a precondition in the policy language; however, the family did complete pre‑test counseling and plans post‑test counseling.",81228,CPT 81228 corresponds to chromosomal microarray (genomic copy number analysis) and best matches the requested CMA.,Yes,"Under FEP coverage criteria CMA is covered for evaluation of unexplained intellectual disability/developmental delay. The patient is a 2‑year‑old with severe intellectual disability, no prior testing is required, the test was ordered by an appropriate provider, and pre‑test counseling was completed, supporting coverage.",1994,1691,3685
Case18257,baseline,without_policy,iter2,BRCA1/2,Patient is explicitly being evaluated for BRCA1/2 testing for hereditary breast/ovarian cancer risk.,Yes,"Cigna BRCA criteria use age at diagnosis; patient had breast cancer at age ≤50, which meets age-based eligibility despite current age being 64.",Not Specified,Cigna's BRCA policy does not restrict ordering to a specific specialty in most cases; the record shows a general practitioner ordered the test and no payer-specific provider-specialty restriction is documented.,Yes,"Patient has a personal history of breast cancer diagnosed at age ≤50, which is a defined medical indication in Cigna BRCA coverage criteria.",Not Specified,"There are no Cigna BRCA-specific prior testing requirements (e.g., prior CMA) that must be completed before BRCA1/2 testing; prior CMA was nondiagnostic but is not required.",No,"Cigna BRCA criteria consider family history of breast/ovarian cancers; the only family history documented is a sibling with short stature, which is not relevant to BRCA eligibility.",No,Cigna typically requires documentation of genetic counseling (pre-/post-test) for hereditary cancer testing; there is no documentation of prior genetic counseling in the record.,81162,"Of the provided CPT options, 81162 most closely corresponds to BRCA1/BRCA2 targeted analysis (e.g., large rearrangement/BRCA-specific testing); other codes correspond to exome/genome or other genes.",No,"Although the patient meets medical and age indications for BRCA1/2 under Cigna, required documentation of genetic counseling is absent; coverage would be denied or held pending required counseling documentation.",1976,1795,3771
Case10075,baseline,without_policy,iter2,CMA,The note explicitly states consideration of chromosomal microarray (CMA) testing to evaluate for an underlying chromosomal or genetic etiology.,Not Specified,"BCBS_FEP CMA coverage policies do not impose an absolute age cut-off for CMA; CMA is used across pediatric ages, and no age‑based exclusion is specified for this 4‑week‑old infant.",Not Specified,BCBS_FEP CMA policies typically do not restrict ordering to a specific provider specialty; the information gives a developmental pediatrician as the ordering clinician but the payer policy does not specify special provider requirements.,No,"BCBS_FEP coverage for CMA is generally limited to specific indications (unexplained developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies). This infant has an isolated meconium ileus and family history of an inborn error of metabolism (suggesting a metabolic disorder), which do not meet the specified CMA indications.",Not Specified,"BCBS_FEP CMA criteria do not define mandatory prior test completion (e.g., karyotype) before CMA; the record notes a prior nondiagnostic CMA, but the policy does not specify required prior testing steps in this scenario.",Not Specified,"While the patient has a sibling with an inborn error of metabolism, BCBS_FEP CMA eligibility criteria do not specify family history/consanguinity as an independent criterion for CMA coverage; therefore family history relevant to CMA eligibility is not specified.",Not Specified,"BCBS_FEP policies do not uniformly mandate documented genetic counseling as a prerequisite for CMA coverage; although pre‑test counseling was completed (and is good clinical practice), specific counseling requirements for coverage are not specified in the policy context provided.",81425,"CPT 81425 corresponds to chromosomal microarray analysis (CMA), which is the test requested.",No,"Under BCBS_FEP CMA coverage criteria, CMA is covered for defined indications (e.g., unexplained developmental delay, intellectual disability, autism, or multiple congenital anomalies). This infant does not meet those criteria (isolated meconium ileus and a family history suggesting a metabolic disorder), and repeat CMA after a prior nondiagnostic CMA is generally not supported without new findings; therefore the test is not covered.",1991,2489,4480
